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Dendritic glycopolymers based on dendritic
polyamine scaﬀolds: view on their synthetic
approaches, characteristics and potential for
biomedical applications
Dietmar Appelhans,*a Barbara Klajnert-Maculewicz,*b Anna Janaszewska,b
Joanna Lazniewskab and Brigitte Voit*ac
In this review we highlight the potential for biomedical applications of dendritic glycopolymers based on
polyamine scaﬀolds. The complex interplay of the molecular characteristics of the dendritic
architectures and their specific interactions with various (bio)molecules are elucidated with various
examples. A special role of the individual sugar units attached to the dendritic scaﬀolds and their density
is identified, which govern ionic and H-bond interactions, and biological targeting, but to a large extent
are also responsible for the significantly reduced toxicity of the dendritic glycopolymers compared to
their polyamine scaﬀolds. Thus, the application of dendritic glycopolymers in drug delivery systems for
gene transfection but also as therapeutics in neurodegenerative diseases has great promise.
1. Introduction
The decoration of various macromolecular scaﬀolds with carbo-
hydrate ligands leads to the fabrication of diverse multivalent
glycoconjugates and glycopolymers (Fig. 1).1–12 Their most
common use is for triggering and inhibiting a large number
of biological phenomena13 induced by an individually arranged
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recognition carbohydrate motif onto dendritic, polymeric, self-
assembled, and other molecular scaffolds,14–16 but also onto
nanoparticle and solid surfaces.17–19 This is strongly motivated
by the fact that multivalent carbohydrate–protein interactions
are mainly involved in a large variety of intercellular recognition
processes, including, for example, bacterial and viral adhesion,
the evaluation of immune response, targeting drugs, cell growth
regulation, cell differentiation, cell–cell interactions, and cancer
cell aggregation, but also the metastatic spread of cancer.20–23
To explore and exploit the desired carbohydrate–protein inter-
actions in the presence of isolated biomolecules (e.g. protein
receptors) and biological entities (cells or tissue), the molecularly
and spatially arranged carbohydrate residues on dendritic scaf-
folds were continuously optimized and verified to better mimic
and match the complementary binding voids of protein receptors
over the last few years. Thus, the inhibition of plant24–27 and
human28,29 lectins, including some other protein receptors on
the cell membrane surface of bacteria and viruses,30–36 can be
triggered depending on the size and generation of dendritic
glycoarchitectures and their surface composition and arrange-
ment of the multivalent carbohydrate shell. For example, this
is highlighted by the preferred occupation of the dendritic
cell surface DC-SIGN or other mannose-binding proteins by
clustered oligomannose dendrons for preventing the cellular
uptake of HIV-1 in dendritic cells.37 Additionally, those glyco-
dendrons can be conjugated to carrier proteins for establishing
vaccines for producing body’s own antibodies that can undergo
molecular interactions of the gp-120 binding domain in HIV-1.
This strategy may be suited for capturing HIV-1 in dendritic
cells (Fig. 2).37 Moreover, recent progress has been achieved in
establishing efficient glycodendrimers as antibacterial agents
for humans34,38 as alternatives to multi-resistant drug molecules
such as, for example, ciprofloxacin and ampicillin.34 In this
regard, mannosylated lysine dendrons, additionally equipped
with a 6-aminohexanoic acid linker between mannose units and
surface groups of lysine dendrons, had been identified to be
the better antagonists against Escherichia coli FimH than the
unmodified mannosylated lysine dendron (Fig. 3).38
There is still a high need to identify key factors determining
the interactions of multivalent dendritic glycoconjugates for
their successful inhibition of protein24–36 and carbohydrate39–41
cell receptors, but also for being able to develop (simplified)
models.14,42 Summarizing the most important key factors recently
presented in some reviews,1,4,5,18,43,44 one can state that a complex
structure–activity relationship between the multivalent dendritic
glycoconjugate and the complementary binding voids of the
(protein) receptors exists. This means that not only are the
mono-, disaccharide or branched oligosaccharide units used
responsible for a high affinity against cell receptors but also the
composition of the linker (aliphatic, aromatic or heterocycles or
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combination of them and other molecular subunits) between
(oligo-)saccharide units and dendritic scaffold has a significant
influence on the final affinity. In some cases linker subunits
such as aromatic or triazole units in dendritic glycoconjugates
contribute to the enhancement of the binding events towards
carbohydrate-binding (cell) protein receptors. For other binding
events, (highly) flexible multivalent oligosaccharide units chemi-
cally fixed to a more rigid dendritic scaffold had been found
to be effective. One can state that in general highly adaptable
dendritic glycoconjugates are involved in the molecular recogni-
tion of the carbohydrate motifs by the various lectins or cell
receptors. On the other hand, the success of highly adaptable
dendritic glycoconjugates also depends on (I) their simultaneous
binding access to dimeric or higher assembled units of receptor
molecules (e.g. lectins) (Fig. 4) and on (II) the ability to cluster
randomly distributed membrane receptors on the cell surface
for inducing signal transduction (Fig. 5).1,2 Such triggered
signal transduction is a helpful tool to initiate the production
of antibodies46 or to deliver other antigens in cells.47 Thus, the
interaction properties of multivalent dendritic glycoconjugates,
based on dendron and dendrimer scaffolds, against isolated lectins
and cell membrane receptors can be characterized by either a low or
a high multivalency (e.g. avidity) and by a strong binding tendency
that can lead to receptor clustering (Fig. 5).2,45
Overall these outstanding interaction profiles of large den-
dritic glycoconjugates against various cell membrane receptors
allow us to use them as drugs per se in diﬀerent therapeutic
fields as functional antigens,6–8,46 antitumor vaccines,6–8,46
antivirals,37 antibacterial/-microbials,35,38 anticancer drugs for
hepatic cancer,48,49 antiangiogenics,50 anti-influenza drugs,51,52 for
inhibition of various toxins,35,36 and for triggering the fibroblast
growth factor activity,53 but they are also applicable as diag-
nostic tools in cancer and for the detection of protein receptors
and viruses.6–8
For the design and fabrication of the dendritic glycoconju-
gates various dendritic scaﬀolds or smaller branched core mole-
cules were used as follows: polyamine dendrons and dendrimers
(poly-L-lysine (Lys), polyamides, poly(amidoamine) (PAMAM),
poly(propyleneimine) (PPI), polypeptides), hyperbranched
poly(ethyleneimine) (PEI), dendritic polyesters from Boltorn, silane
scaﬀolds, cyclodextrin and cyclopeptide cores, the benzene core,
the hexaphenylbenzene core, the porphyrin core, the cyclotri-
phosphazene core, the tetraphenylmethane core, and others.
Under the shadow of drugs per se glycodendrimers can be
generally considered as (anti-adhesive) drugs for initiating the
inhibition of lectins, viruses and bacteria and other molecular
interactions (Fig. 4 and 5).1,33,35 On the other hand dendritic
glycoconjugates, carbohydrate-containing dendronized polymers,
and hybrid materials of various polysaccharides over the last
year have been also established in various application fields.
Thus they have been used as drug delivery systems,10,54–95
biosensors,15,16,19,96–101 and imaging agents,1,18,102–106 but also
as a base in biohybrid structures obtained through non-covalent
and biological conjugation,91,92,107,108 as sugarballs for H-bond-active
therapeutics and diagnostics for brain disease,109–118 as supramole-
cular structures by (defined) self-assembly119–121 or host–guest inter-
actions,122 and in thin film technology for introducing specific
interactions with small analyte molecules or proteins.123,124 The
PPI, Lys, and PAMAM polyamine dendrimers, but also branched
poly(ethyleneimines) (PEI) are the dominating dendritic core
scaffolds to realize the desired dendritic glycopolymers for these
growing research fields (Fig. 6–8). Carbohydrate decoration of
Fig. 1 Selected dendritic glycoconjugates usable as (anti-adhesive) dendritic glycoconjugates, drug delivery systems, and polymeric therapeutics.
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dendritic polymers was developed as an alternative way to
PEGylation, which is so far the dominating choice to establish
highly biocompatible delivery systems and therapeutics for
in vitro and in vivo application.125–133
This review will elaborate and highlight the recent progress of
dendritic glycopolymers based on polyamine scaﬀolds (preferred
PPI; less PAMAM (Fig. 9) and PEI) with regard to their use in various
biomedical application fields (complexation and biological proper-
ties, anti-Alzheimer agents, anti-prion agents, drug delivery). Firstly,
the synthetic approaches of these dendritic glycopolymers are very
concisely presented and the newest synthetic development is
shortly marked. Additionally, the biological and delivery properties
of carbohydrate-modified dendritic scaﬀolds are compared with
non-carbohydrate-modified dendritic polymers to better identify
their potential use in the field of biomedical applications. More-
over, the driving forces of the molecular interactions of dendritic
glycopolymers against drugs, analyte molecules, proteins or amylo-
idogenic peptides will be emphasized.
2. Synthetic aspects of dendritic
glycopolymers
Recent progress in the design and fabrication of glycodendrimers is
strongly interwoven with newly established synthetic approaches
towards linear and dendritic polymers,134–140 especially of
dendrimers, and to generate larger dendrimer generations with
the lowest synthetic efforts.137,141–145 Under the term ‘‘click
reaction’’146 various easily performed and highly efficient chemical
conjugation strategies for the synthesis of dendritic scaffolds have
been successfully used such as yne–azide, thiol–ene, thiol–yne,
amine–epoxy, but also the surface functionalization of dendritic
polymers137,141–145 benefits from these organic reactions. More
recently, straightforward approaches have been developed using
at least two click reactions for the synthesis of the dendritic
Fig. 4 Composition of anti-adhesive dendritic glycoconjugate and their
valency (accessible sugar units) dictate the multiple binding sites in oligomeric
protein receptors (e.g. lectins).
Fig. 3 Anti-adhesive dendritic glycoconjugate – Highly flexible mannose-
coated lysine-based glycodendron as an antagonist against Escherichia coli
FimH. Reproduced with permission from ‘‘A. Papadopoulos, T. C. Shiao and
R. Roy, Mol. Pharmaceutics, 2012, 9, 394–403’’. Copyright 2012 American
Chemical Society.
Fig. 2 Possible biological molecular interactions of oligomannose dendrons
as (anti-adhesive) dendritic glycoconjugates to suppress HIV-1 infection.
(a) Possible conjugation to proteins and use as vaccines. (b) HIV-1 infection
by HIV-1 binding to dendritic cell-surface DC-SIGN or other mannose-
binding proteins to enhance CD4+ T cell infection. (c) Possible inhibition of
the binding of HIV-1 to the dendritic cell-surface DC-SIGN or other
mannose-binding proteins to prevent dendritic cell-enhanced CD4+ T
cell infection. Reproduced with permission from ‘‘S.-K. Wang, P.-H. Liang,
R. D. Astronomo, T.-L. Hsu, S.-L. Hsieh, D. R. Burton and C.-H. Wong,
Targeting the carbohydrates on HIV-1: Interaction of oligomannose
dendrons with human monoclonal antibody 2G12 and DC-SIGN Proc.
Natl. Acad. Sci. U. S. A., 2008, 105, 3690–3695’’. Copyright 2008 National
Academy of Sciences. USA.
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scaffolds142,144,145 as well as for the decoration of dendrimers
with various carbohydrates.147–150 A kind of onion peel glyco-
dendrimer, using several times the same click reaction for the
fabrication of larger dendrimer generation, has been established
by the groups of Hawker, Malkoch and Dondoni (Fig. 10),149
while the group of Roy realized a similar highly multivalent
onion peel dendrimer by using only one time an efficient click
reaction.151 An efficient orthogonal approach by using thiol–
ene and SN2 reactions was recently introduced to accelerate the
growth of multifunctional dendrimers and dendritic glycoconju-
gates.152 Here, the group of Schlaad introduced carbohydrates as
side groups in a polymeric backbone for the first time by UV
irradiation or by day light.153,154 Moreover, a photo cyclization
reaction was also adaptable to introduce carbohydrate-modified
dendrons along a polymeric backbone with a high density of
carbohydrate functionalization.155
Various reviews1,4–8,14–16,20,30–34,40,43,44,47,156–166 can be referred
to for elaborating the recent progress in the design and fabrica-
tion of dendritic glycoconjugates and the variations achieved with
regard to linker chemistry and size, shape, functionality and
flexibility or rigidity of the dendritic scaffold, especially for the
design and fabrication of anti-adhesive dendritic glycoconjugates
(Fig. 2 and 4). One can state that all conventional and modern
synthetic tools are applicable for the chemical coupling of carbo-
hydrates to any dendritic scaffold and to transform functional
groups in carbohydrate units and their derivatives ready for
the functionalization of dendritic scaffolds. As a few highlights
are emphasized (I) various solid phase approaches,38,167,168
combined with enzymatic support,169 to fabricate very complex
oligosaccharide architectures, (II) the chemical and enzymatic
post-modification of dendritic scaffolds to introduce final
carbohydrate units105,170–172 or peptide recognition sequences173
and (III) the chemical conjugation of antigens as part of the
linker units between the dendritic scaffold and the complex
oligosaccharide scaffold.8,37,46,93,94 But also sulfur chemistry
can accelerate and strengthen the design, fabrication and
application of dendritic glycoconjugates.43
In comparison to the often intensive synthetic eﬀorts for the
fabrication of dendritic glyco-scaﬀolds as anti-adhesive drugs,
the synthetic pathways to establish dendritic glycopolymers, for
Fig. 6 Common and contrary structural features of dendritic polyamine
scaﬀolds decorated with various (oligo-)saccharide units. Dendritic poly-
amine scaﬀolds are dendrons and dendrimers (PPI, PAMAM, Lys, polyamide)
and also hyperbranched structures (PEI) with peripheral amino groups.
Dendritic glycoconjugates are considered as open shell architectures
following the declaration in the text (Section 3) and Fig. 7. One main
structural feature of dendritic glycopolymers is the direct coupling of
(oligo-)saccharide units to the dendritic polyamine scaﬀold in opposite to
(anti-adhesive) dendritic glycoconjugates.
Fig. 5 Dendritic glycoconjugates are able to bridging multiple surface
receptors, clustering them, and initiating signal transduction.
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example, as drug delivery systems10,54–95 and therapeutics and
for diagnostics in the field of brain disease109–118 are directed
preferentially to use fast and easily available conversion steps to
achieve carbohydrate modification of dendritic PPI, PAMAM,
PEI and Lys scaffolds. The most favorite conjugation tool for the
carbohydrate modification of dendritic structures is the reduc-
tive amination by using (I) NaBH3CN in sodium borate buffer
at about pH 8 and room temperature,54,57,62–65,67,70,76,82,174 (II)
borane*pyridine complex in sodium borate buffer at about
pH 8 for several days at 50 1C (ref. 10, 11, 55, 56, 60, 61, 77
and 108–124) or (III) simple use of acetate buffer at pH 4 and
room temperature or at pH 4 and 60 1C for several hours78,79,83
to convert the intermediate enamine into secondary and tertiary
amino groups bearing the desired carbohydrate units (Fig. 7
and 8). For the carbohydrate modification of PEI another
important synthetic tool has been established by converting
hyperbranched PEI with various carbohydrate phenyl isothiocya-
nates (Fig. 6).66,68,69,73 For preparing PAMAM glycodendrimers
as a drug delivery system85–94 various carbohydrate units with
acid, lactone or phenyl isothiocyanate groups were converted
Fig. 7 Characteristics of open shell and dense shell PPI glycodendrimers. Open shell is characterized by peripheral amino group wearing maximal
one (oligo-)saccharide unit in PPI-OS-Mal G3, while peripheral amino groups in dense shell of PPI-DS-Mal G3 possess two chemically coupled
(oligo-)saccharide units.
Fig. 8 Synthesis and characteristics of (oligo-)saccharide-modified
hyperbranched PEI. Decreasing cationic surface charge: PEI 4 PEI with
structure C 4 PEI with structure B 4 PEI with structure A.
† Authors of this RSC review strongly recommend the nomenclature of
‘‘poly(propylene imine) dendrimers’’ suggested by D. A. Tomalia and M. Rook-
maker published, in Polymer Data Handbook, ed. J. E. Mark, Oxford University
Press, New York, 2nd edn, 2009, pp. 979–982. The nomenclature for Tomalia-
type PAMAM dendrimers and other dendrimer architectures can be adopted
also for PPI dendrimers to provide a commonly usable nomenclature and
description of all dendrimer structures for predicting the right number of surface
groups of a perfect dendrimer. In the literature, most nomenclature of PPI
dendrimers is addressed with a higher generation number (+1) in comparison
to PAMAM dendrimers. Here, in this review authors use the nomenclature of PPI
dendrimers suggested by D. A. Tomalia and M. Rookmaker. This means we
present results obtained by 1st to 4th generation PPI dendrimers described in the
previous literature as 2nd to 5th generation PPI dendrimers, while in our previous
studies, but also in many studies by others the old version of nomenclature for
PPI dendrimers (2nd to 5th generation PPI dendrimers) has been used. We
motivate all to use the right nomenclature for PPI dendrimers in their future
studies.
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with the peripheral amino groups of the dendritic PAMAM
scaffold into the desired dendritic glycoconjugates (Fig. 6).
More recently, hydrazide-modified PAMAM dendrimers were
used for the direct conjugation of reducing saccharides under the
preservation of the cyclic scaffold of the saccharides, but with
less efficiency in increasing the generation number (Fig. 6).175
The introduction of a-, b- or g-cyclodextrin units on amino-
functionalized dendritic PAMAM scaffolds follows under the
principle of SN2 reactions.
92 Thus, various carbohydrates (glucose,
maltose, maltotriose, maltohexaose, maltoheptaose, galactose,
lactose, mannose, mannobiose, cellobiose, tetragalactose, sialic
acid, N-acetyl glucosamine, lacto-N-difucohexaose or cyclodextrin)
have been successfully introduced. Interestingly, biologically
active galactose units were preferentially realized on dendritic
scaffolds by the introduction of the disaccharide lactose. After
attaching lactose under reductive amination or phenylisothio-
cyanate conditions, the cyclic form of the galactose rings
remains and allows for the specific galactose molecular recog-
nition in the course of ligand-mediated drug targeting.62,65,67–72
In contrast to this, mannose and galactose, when they are
directly introduced on the dendritic PPI and Lys scaffold under
reductive amination conditions, they do not retain their
active cyclic ring conformation as targeting ligands against cell
lines.78,79,83,95 However, the mannose units, but also sialic acid,
were established on the dendritic PPI scaffold surface in the
active form by multi-step reactions.80,83,176
One final consideration is directed to the eﬃciency of the
applied one-pot reactions mentioned above to establish the
desired dendritic glycoconjugates.10,54–95,108–118 The conversion
of dendritic polyamine scaffold based on amidation, phenyl
isothiocyanate derivatives and lactone derivatives is more or less
quantitative (Fig. 6) when following the experimental protocols.
These results are impressively supported by the design and
fabrication of other dendritic glycoconjugates applicable as
anti-adhesive drugs.9,25–27,159,177 Reductive amination is an easily
applicable synthetic method to couple carbohydrate units on the
dendritic polyamine scaffold, while the control over the attached
numbers of carbohydrate units on the dendritic polyamine
scaffold can be partly challenging when only aiming for mono-
substitution of primary amino groups. In this case optimization
is needed by adjusting the equivalents of carbohydrate units
(r1 equivalent per peripheral amino group) or the reductive
agent for the desired composition of dendritic glycoconjugates
(Fig. 7 and 8).10,78,79,83,119,178 Moreover, reductive amination is
also highly efficient to generate dense carbohydrate shells
around dendritic polyamine scaffolds of hyperbranched PEI
and PPI and Lys dendrimers,10,55,108–111,179,180 where, finally,
the former peripheral primary amino group is converted into a
tertiary amino group bearing two carbohydrate units (Fig. 7
and 8). This type of dendritic glycopolymers is only available
under the use of excess carbohydrate units (10–40 equivalents
per amino group) and excess reductive agent.10,55,108–111,179
This kind of densification of carbohydrate units on dendritic
polyamine scaffolds is only comparable with the recently
described work of Malkoch and Dondoni.150 In their case
peripheral alkyne groups on a polyester dendrimer surface were
used to introduce two carbohydrate units on one alkyne
by thiol–yne conversion conditions. With their method less
excess carbohydrate units (4 equivalents per yne group and
r0.3 equivalent photo initiator per yne group) under UV
irradiation are needed to fabricate this specific dense shell
glycoarchitecture.150
Fig. 10 Various onion peel dendrimers with diﬀerent surface groups.149 Reproduced from ref. 149 with permission from John Wiley and Sons.
Fig. 9 Chemical structure of 2nd generation poly(amidoamine) (PAMAM)
dendrimer with 16 terminal amino groups used for the fabrication of mannose-
and a-cyclodextrin-modified 2nd generation PAMAM dendrimer.86,88
Chem Soc Rev Review Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
D
ec
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
3/
05
/2
01
5 
14
:2
5:
23
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Chem. Soc. Rev. This journal is©The Royal Society of Chemistry 2014
3. Characteristics of dendritic
glycopolymers
The knowledge about the interaction characteristics of dendritic
glycopolymers in solution is essential for their successful use as
a drug delivery system and therapeutics and in diagnostics in the
field of neurodegenerative disease. Furthermore, it is also desir-
able to get insight into in vitro interactions towards biologically
active molecules (e.g. proteins or nucleic acids). Therefore, the
molecular characteristics of dendritic glycopolymers10,54–95,108–124
will be presented here and will be compared to those of the
highly elaborate dendritic glycoconjugates applied as anti-
adhesive drugs.19,29–37
For both, the well-known anti-adhesive dendritic glycocon-
jugates1,6–8,20,30–38,46,48–53 and the often less defined dendritic
glycopolymers used in other biomedical application fields,10,54–124
the terms open shell and dense shell dendritic glycopolymers
will be used as a common feature to describe the molecular
characteristics (Fig. 6–8). Both terms, dense and open shell
dendritic glycopolymers, were recently introduced by the group
of Appelhans and Voit.10,55,56,108–111,114 It is easily described by
the degree of (oligo-)saccharide functionalization of dendritic
polyamine scaffolds (PPI dendrimers and hyperbranched PEI).
In the ‘‘dense shell’’ architecture the primary amino groups of the
dendritic polyamine scaffolds are converted into tertiary amino
groups bearing two chemically coupled (oligo-)saccharide units
(disubstitution) (Fig. 7).10,109 Additionally, in the case of hyper-
branched PEI, secondary amino groups are also converted into
tertiary amino groups bearing a single saccharide unit (Fig. 8).10
In contrast to this the ‘‘open shell’’ architecture is characterized
by the conversion of primary amino groups into secondary
amino groups only bearing one chemically attached (oligo-)-
saccharide unit (monosubstitution) (Fig. 7 and 8).10,109 Most of
the dendritic glycopolymers used as drug delivery systems and
therapeutics and diagnostics for neurodegenerative
disease,10,54–59,62–76,78–107,110,113,114,119–124 belong to the type of
open shell dendritic glycopolymers, while some perfectly
branched glycodendrimers, mainly applied as sugarballs in the
field of neurodegenerative disease109–118 and in drug delivery
system,56,60,61,77 possess a dense shell. Most of the dense shell
glycoarchitectures used in biomedical applications are based on
PPI dendrimer scaffolds.109–118
One specific key issue of the reductive amination is that the
reducing unit of mono-, di- and oligosaccharides is directly
connected to the primary and secondary amino groups in the
dendritic polyamine scaﬀolds. Therefore, there is usually no
spacer between the coupledmono-, di- and oligosaccharide units
and the corresponding dendritic polyamine scaﬀold (Fig. 6).
The situation is similar using the conversion of lactones for
glycosylation.90 With these synthetic tools a preferred shielding
eﬀect against the dendritic polyamine scaﬀold in terms of surface
charge reduction can be achieved10,55,56,109–111 and the complexa-
tion properties of the core are better supported.79,80,84,108,181–183
On the other hand, the introduction of targeting ligands is also
possible.62,70 Overall, these specific dendritic glycopolymers10,54–95,108–124
are commonly characterized by (oligo-)saccharide units directly
linked to the dendritic polyamine scaffold (Fig. 7 and 8) or linked
via a short alkyl80,83 and aromatic66,68,69,74 spacer (Fig. 6).
In contrast to this, the well-known anti-adhesive dendritic
glycoconjugates1,6–8,20,30–38,46,48–53 can be assigned to an open shell
architecture since most of their peripheral functional groups
possess only one (oligo-)saccharide unit (Fig. 6). Secondly, the
(oligo-)saccharide units are preferentially linked via a spacer to the
peripheral functional groups of various dendritic architectures
(Fig. 6) to establish highly accessible molecular recognition
carbohydrate units on the dendritic scaffolds for undergoing
desired protein–carbohydrate interactions. The molecular com-
position of the spacer can vary widely (Fig. 6). The nature of the
spacer depends on the targeted protein receptors (isolated or
integrated in the cell membrane) and the type of biological
entities (viruses or bacteria) to be investigated. Finally, different
dendritic molecular scaffolds ranging from very rigid to highly
flexible were successfully applied for this purpose (Fig. 2, 3 and 6).
Not only small branched core molecules or dendrons,1,4 but also
larger dendrimers are reported for enhanced binding affinities at
very low concentration in the nanomolar range of anti-adhesive
dendritic glycoconjugates. Overall, the perfect interplay of these
different molecular parameters is a pivotal point to achieve
highly multivalent dendritic glycoconjugates that can adapt to
the chemical and biological space of protein and carbohydrate
receptors in various biological environments. Most of the open shell
anti-adhesive dendritic glycoconjugates have different structural and
molecular features than the above mentioned open shell dendritic
glycopolymers used for drug delivery systems.
Further attention is now directed to the molecular charac-
teristics of open and dense shell dendritic glycopolymers, based
on PPI dendrimer and PEI,10,55,56,60,61,76–84,108–124 used as a
drug delivery system and as sugar balls for therapeutics and
diagnostics in neurodegenerative diseases. Playing with the
degree of mono-, disaccharide and oligosaccharide functionali-
zation on those dendritic polyamine scaffolds, surface charge or
charge density of PPI glycodendrimers is tunable from positive
for open shell glycodendrimers to neutral for dense shell glyco-
dendrimers.109,114 Open and dense shell PPI glycodendrimers can
be in addition decorated with anionic sulfate groups.114,184,185
Dense and open shell dendritic glycopolymers based on PEI
(Fig. 8) possess pH-dependent cationic surface charge and
charge density over a broad pH range [2 to isoelectric point
(8–9)] tailored by the given (oligo-)saccharide architectures A, B
and C.10,55,57–59,62–75 Architecture A, meaning dense shell archi-
tecture, has the lowest cationic charge and architecture C,
meaning an open shell architecture with even remaining primary
amines, possesses the largest cationic charge within this series.
Overall, these dendritic glycoarchitectures preferentially exist as
non-aggregated macromolecules in aqueous solution and under
physiological conditions.10,55,109,118 The molecular sizes of both
types of dendritic glycopolymers are in the lower nanometer
range: r8 nm for the largest generation of PPI glycodendri-
mers109,118 and r12 nm for glycoarchitectures based on a PEI
core with a molecular weight of 25 kDa.10,186 A surprising result
is that the diameter of dendritic glycopolymers (PPI as well as
PEI based) does not change by varying the pH.186
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SAXS and DLS studies verified that open and dense shell PEI
glycoarchitectures can be considered as core–shell architec-
tures.186 This implies that the oligosaccharide units of the
open and dense shell are mainly located in the outer sphere of
these PEI glycoarchitectures. Moreover, the (oligo-)saccharide
decoration of PEI induces an enlargement of the dendritic
scaffold itself.10,186 Core–shell PEI glycoarchitectures10,55,56,186
can theoretically undergo ionic as well as H-bond-driven
interactions, depending on the shell density. These specific
molecular characteristics are of importance for the complexa-
tion and delivery of drugs,10,55,56,181,182 but can also lead to
morphological transformation of anionic vesicles into worm-
like networks.187
In line with this, dense shell PPI glycodendrimers can be also
ascribed as core–shell architecture as supported by various
studies.109,111,114,118 Polyelectrolyte titration experiments prove
that anionic polyelectrolytes are not able to penetrate the dense
maltose shell of PPI glycodendrimers and thus cannot com-
pensate the cationic charge of the PPI core molecule. Only very
small molecules such as water or other nutrients are capable
of diffusing through the dense oligosaccharide shell of glyco-
dendrimers. Furthermore, the cationic charge of the dendritic
PPI scaffold in dense shell glycodendrimer was only determinable
by pH streaming potential measurements,110 but not by zeta
potential measurements under physiological conditions.108 In
general, dense shell PPI glycodendrimers can be considered as
amphiphilic macromolecules with a cationic core and a neutral
and H-bond-active shell (Fig. 11).
Thus, preferably H-bond-driven surface interactions of dense
oligosaccharide shell can be assumed for the biological inter-
actions of dense shell glycodendrimers.109–118 In line with this,
molecular modelling and theoretical calculations confirmed a
dense oligosaccharide shell for this class of glycodendrimers
where only few oligosaccharide units are back folded and
wrapped by the dendritic PPI scaffold (Fig. 11: indicated by a
purple color in the PPI-DS-Mal G4 image). For this purpose
dense shell glycodendrimers were modeled in a water droplet.114
On the other hand open shell PPI glycodendrimers are char-
acterized by a cationic surface charge as well as an H-bond-
active surface.108,110
4. Interactions of dendritic
glycopolymers with proteins
Interaction of dendrimers with biological systems determines
their potential biomedical application. This also includes their
toxicity towards cells. Thus, it is of crucial importance to find the
right balance between favorable and detrimental biological
eﬀects evoked by dendrimers. Undoubtedly, interactions of den-
dritic nano-sized molecules with proteins present a biomedical
potential. For instance, dendrimers can inhibit fibrillation of
proteins involved in neurodegenerative disorders188,189 or bind
surface proteins of pathogens limiting the spread of infection.190
Since modification of cationic surface groups of dendrimers
with neutral or anionic moieties decreases their cytotoxicity,191,192
the ability of maltose-modified dense shell PPI glycodendrimers
(G1–G4) to interact with human serum albumin (HSA) was
examined and compared to naked PPI.109 Surprisingly enough,
the results indicated that there is no significant difference in the
strength of interactions between unmodified or sugar-coated den-
drimers and HSA. PPI G1 and maltose-modified PPI G1 and G2 did
not interact with the studied protein. Naked PPI G2 interacted
weakly with HSA, while unmodified andmaltose-coated dendrimers
PPI G3 and G4 exhibited strong interactions with HSA. These data
also point out that dendrimer–HSA interactions are generation-
dependent and begin from G3. It is likely that higher generations
possess proper size, globular shape and rigidity to effectively
bind to the protein molecule. Moreover, it is proposed that
besides electrostatic interactions between positively charged
dendrimers and negatively charged HSA, carboxylate groups
and oxygen atoms of the amide groups of the proteins partici-
pate in forming hydrogen bonds.109
Further studies on the impact of PPI dendrimers on protein
properties were conducted using unmodified PPI G3, as well as
PPI G4, including open and dense shell glycodendrimers decorated
with maltose. A model protein, liver alcohol dehydrogenase
(LADH) was applied to study the interactions with the dendri-
mers.193 This protein possesses two tryptophan (Trp) residues,
one on the outside (Trp-15), and one buried inside the protein
structure (Trp-314). Changes in the protein structure near Trp-15
and to amuch higher degree near Trp-314 are reflected in changes
in fluorescence spectra. Moreover structural reorganization in
Fig. 11 Molecular modelling showing the radial distribution of maltose units
had an high impact in understanding the molecular interaction of dense
shell glycodendrimer PPI-DS-Mal G4.114 The variousmolecular interactions of
PPI-DS-Mal G4 are outlined considering the low permeable sugar shell
for limited ionic interactions with cationic PPI core.109–111 Adapted with per-
mission from ‘‘J. M. McCarthy, B. Rasines Moreno, D. Filippini, H. Komber,
M. Marek, M. Cernescu, B. Brutschy, D. Appelhans and M. S. Rogers, Biomacro-
molecules, 2013, 14, 27–37’’. Copyright 2013 American Chemical Society.
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the proximity of Trp-314 can be detected based on room tempera-
ture tryptophan phosphorescence (RTTP).194 The results showed
us that none of the tested dendrimers quenched Trp fluorescence
of LADH, indicating that the fragment of protein in the proximity
of Trp is not involved in the interactions with dendrimers. RTTP
analysis revealed that all PPI caused similar decrease in RTTP
along with increasing concentration. Only in the concentration
range of 10–25 mMunmodified PPI G4 had stronger impact on the
tested parameter than the glycodendrimers. The decrease in RTTP
points out that the dendrimers interact with the protein and that
the native fold of LADH became more flexible as a result of
dendrimer binding. Moreover, a stronger effect of the naked PPI
dendrimer at some concentration range indicates an involvement
of electrostatic forces in dendrimer–protein association. However,
similar influence on RTTP of all dendrimers at other concentra-
tions implies that other types of bonds, such as H-bonding,
van der Waals and hydrophobic forces also play a role in PPI
dendrimer–LADH interactions. The fact that no changes were
detected in the fluorescence, while a decrease in RTTP was observed,
is likely to result from a much longer lifetime of phosphorescence
than fluorescence. Circular dichroism analysis revealed small
changes in the secondary structure of LADH dependent on the
type of PPI dendrimer added. Unmodified PPI dendrimer caused
the strongest increase in b-sheet content and a small decrease in
a-helix structures. On the contrary, dense shell PPI fully coated
withmaltose had no impact on the secondary structure of LADH.
The results indicate that electrostatic interactions between the
protein and cationic peripheral amino groups of PPI dendrimers
are responsible for alterations in the secondary structure.
Furthermore, upon addition of all dendrimers, an increase in the
hydrodynamic diameter of the molecules/complexes in solution
was observed; in the case of uncoated PPI even formation of larger
aggregates was evident and the formed complexes were shown to
be stable for 12 hours. Addition of dendrimers had little influence
on zeta potential of complexes. In summary, the results demon-
strate that all types of tested dendrimers are able to interact with
LADH starting from generation 3, although unmodified PPI G3
possesses the greatest affinity to the protein.193
Influence of open shell (OS), dense shell (DS) and naked PPI
G3 on the thermal stability of a model protein hen white egg
lysozyme (HWEL) was also examined and compared with the
impact on the protein of anionic PAMAM G3.5. Moreover, the
availability of lysozyme Trp to fluorescence quenchers in
the presence of dendrimers was studied. HWEL is characterized
by a positive net charge under physiological conditions, although
it contains both positively and negatively charged areas. To assess
the eﬀects of dendrimers on the thermal stability of HWEL
diﬀerential scanning calorimetry (DSC) and circular dichroism
(CD) methods were employed. The results show some changes in
the melting temperature of HWEL after addition of dendrimers.
DSC analysis revealed that the biggest eﬀect was observed after
addition of uncoated PPI dendrimer, while PPI-DS had no influ-
ence on the studied parameter. CD analysis demonstrated the
greatest impact of PAMAM G3.5 on the content of a-helix upon
heating, while for PPI dendrimers the eﬀect was dependent on
the degree of surface modification (PPI 4 PPI-OS 4 PPI-DS).
The changes in the protein secondary structures (a-helix and
b-sheet contents) upon heating were again most pronounced in
the presence of PAMAM G3.5 and the lowest in the presence of
PPI-DS. These eﬀects are likely to stem from electrostatic inter-
actions between positively charged lysozyme and a negatively
charged dendrimer. However, HWEL also possesses anionic
areas which enable binding of cationic PPI dendrimers. Further-
more, CD spectra of lysozyme in near-UV, which reflect changes
in the environment of aromatic acid residues, were altered to
the greatest degree upon addition of PAMAM G3.5. Additionally,
all tested dendrimers have shown to decrease the accessibility of
lysozyme tryptophan residues to quenchers, indicating interaction
between dendritic macromolecules and parts of the protein where
Trp residues are located (near the surface). Generally, PPI-DS with
the neutral surface can bind to HWEL, but mainly by hydrogen
bonds and not electrostatic interactions like the rest of the studied
dendrimers. Due to the nature of interactions, weaker in compar-
ison to other dendrimers, the dense shell PPI glycodendrimer does
not change the secondary structure of the protein. On the other
hand, the strength of interaction between unmodified PPI and
lysozyme and PAMAM G3.5 and the protein is very similar due
to electrostatic interactions with negatively or positively charged
regions of lysozyme, respectively.195
5. Biological properties and
biocompatibility of dendritic
glycopolymers
The following section is intended to be a critical review of biological
properties in vitro and in vivo of some dendritic glycopolymers,
including their potential to cross blood–brain-barrier.
Toxicity in vitro
Dendritic polymers are excellent candidates for nanomedical
applications. Unfortunately, their use might be limited due to
high cytotoxicity. Cytotoxicity of dendritic polymers is depen-
dent on the number and nature of functional surface groups, so
they can exhibit high toxicity if they possess cationic terminal
groups and show slight or no toxic eﬀects when their surface is
anionic or neutral.196,197 Appropriate modifications of the dendritic
polymers surface can significantly reduce their toxicity. Coating
the surface with sugar units is one of the methods available to
obtain less toxic compounds.200
Modification of amino-terminated PPI dendrimers, as a parti-
cular subgroup of dendritic polymers, by coupling two maltose
units to one surface amino group via a simple one-pot method,
resulted in a very significant reduction of toxicity.109 For compar-
ison reasons two types of dendrimers were studied: cationic PPI
dendrimers with open and globular shape, flexible dendritic
scaﬀolds and back-folding properties and nearly neutral dense
shell PPI glycodendrimers interacting preferentially by hydrogen
bonding. The most important eﬀect was the lack of hemolytic
activity, under the experimental conditions at concentrations
of 3 and 6 mg mL1, demonstrated by modified dendrimers
PPI-DS-Mal G1 and PPI-DS-Mal G3. Whereas in the case of
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unmodified amino-terminated PPI dendrimers for the same
concentrations the level of hemolysis was 50 and 70% for G1
and 55 and 85% for G3, respectively. This can be explained by
the formation of a densely organized maltose shell on the PPI
dendrimers surface that separated erythrocytes from the toxic
PPI cores. These results are in agreement with previous studies
in which modification of PPI G4 dendrimers with mannose and
galactose, considered as open shell cationic PPI glycodendri-
mers (Fig. 7), also diminished hemolytic activity. Additionally,
the analyzed mannosylated dendrimer possessed only minor
cytotoxic activity against VERO cells, since only a few percent
reduction of cell viability was observed for concentrations that
exceeded 100 mg mL1.79
Further studies of amino-terminated andmaltotriose-modified
PPI dendrimers confirmed that hemotoxicity of dendrimers
was concentration-, generation-, and time-dependent.198 For
the biological research three types of the G3 PPI dendrimers
were used: unmodified and modified with approximately 35%
(open shell) and 90% (dense shell) maltotriose units. The study
was carried out in the presence of human serum albumin (HSA)
or human plasma or in whole blood. Maltotriose-modified PPI
dendrimers were characterized by lack of hemolytic activity
similarly as other sugar modified dendrimers. In addition they
had a minor impact on lymphocyte proliferation and platelet
aggregation. The unmodified PPI dendrimer, however, was
found to be the most hemolytic because its 60 mM concen-
tration caused even 80% of hemolysis after 24 hours of incuba-
tion whereas the same concentration of open and dense shell
dendrimers modified with maltotriose caused only 12 and 38%
of hemolysis, respectively. The presence of human serum
albumin (HSA) or human plasma or whole blood significantly
reduced (up to 90%) the extent of hemolysis observed by all
analyzed dendrimers. Interestingly, the increase in the degree
of surface modification was not proportional to the decrease in
hemolysis which was confirmed by changes in the erythrocytes
morphology. From echinocytic transformations through cell
aggregation to cluster formation, erythrocyte’s shape was also
dependent on the dendrimer’s type and concentration. The
untreated cells had their normal physiological biconcave disc
shape and neither aggregates nor echinocytes were observed,
whereas 24 hour incubation with 30 mM concentration of the
unmodified PPI dendrimer and dense shell PPI glycodendrimer
led to cluster formation. Additionally, unmodified PPI dendri-
mers significantly inhibited lymphocyte proliferation even at
low 1 mM concentration, in contrast to glycodendrimers that
only slightly inhibited cell proliferation. The sugar modifica-
tion of PPI dendrimers impressively reduced their ability to
induce platelets’ aggregation, in the case of PPI-DS-Mal-III G3
even to zero, whereas the aggregation caused by the unmodified
PPI dendrimer was comparable with that of trypsin, even at the
lowest dendrimer concentrations.
These results are in agreement with previous studies in which
PPI-OS-Gal G3 and G4 (Fig. 7) in comparison to unmodified PPI
dendrimers showed negligible hemotoxicity. Modification with
galactose units significantly reduced hemolysis to 10 and 7.1%
for both generations, respectively.78
Influence of maltotriose modification on the cytotoxicity of
PPI G3 has been studied as a continuation of the research that
aims to define the biological properties of sugar-modified PPI
dendrimers.199 Cytotoxicity profiles of unmodified amino-
terminated PPI G3 and maltotriose-modified dendrimers, PPI-
OS-Mal-III G3 and PPI-DS-Mal-III G3 (Fig. 7), were compared
with acid-terminated PAMAM G3.5 and amino-terminated
PAMAM G4 dendrimers. Modified PPI dendrimers revealed
minor cytotoxicity against a normal Chinese hamster ovary
CHO cell line and unexpectedly greater cytotoxicity against a
moderately doxorubicin and cisplatin resistant human ovarian
carcinoma SKOV3 cell line. As predicted, anionic acid termi-
nated PAMAM G3.5 were found to be less toxic than cationic
amino-terminated PAMAM G4. The anionic PAMAM G3.5, open
shell PPI glycodendrimer and the dense shell PPI glycodendri-
mer were negligibly toxic towards the CHO cell line in a
concentration range of 0.1–300 mM, so the IC50 value could
not be calculated, whereas only very low concentration (o8 mM)
of cationic dendrimers was needed to achieve the IC50. The IC50
data for the SKOV3 cell line confirmed that this moderately
resistant cell line was less susceptible to cationic amino-
terminated PPI G3 and PAMAM G4 dendrimers than the non-
resistant CHO cell line. At the same time, for SKOV3 cell line
open shell and dense shell PPI dendrimers were sufficient to
evaluate the IC50 value at concentrations of 100 and 145 mM,
respectively, while for non-toxic anionic PAMAM G3.5 it was
impossible to calculate the IC50 value.
Other studies also reported high toxicity of unmodified PPI
G3 and PAMAM G4 dendrimers for three cancer lines B16F10,
CCRF and HepG2 and lack of toxicity for PAMAM G3.5 towards
any cell lines in the studied concentration range.200 Similarly to
studies for PPI-Mal III G3, functionalization of PPI dendrimers
with glycine, phenylalanine, mannose and lactose resulted in a
reduction of cytotoxicity in comparison to the unmodified PPI
G4 dendrimer. For PPI G4 dendrimers modified with glycine,
phenylalanine, and lactose, IC50 values were one hundred times
lower and in the case of mannose modification still fifty times
lower compared to the unmodified PPI G4 dendrimer.201
Mechanism of cytotoxicity of unmodified PPI dendrimers is
believed to be related to the generation of reactive oxygen
species (ROS) and damage of the mitochondria. Therefore, an
additional study was performed to examine the ability of PPI
glycodendrimers to induce ROS generation, changes in mito-
chondrial membrane potential and generation of apoptotic cell
death. The obtained results were in good agreement with
previous cytotoxicity findings. Open shell PPI and dense shell
PPI dendrimer caused ROS generation, changes in mitochon-
drial membrane potential and enhanced the amount of apop-
totic and necrotic cells in the SKOV3 cell line.199
In summary PPI glycodendrimers do not show toxic eﬀects
towards normal cells that are characteristic targets for the
unmodified amino-terminated PPI or PAMAM dendrimers. At
the same time PPI glycodendrimers exhibit higher cytotoxicity
against cancer cells. This observation supports the conclusion
that the analyzed glycodendrimers may be suitable for medical
applications as anticancer agents.
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Another example of the protective eﬀect of maltotriose
modification is provided by DNA damage and repair studies.202
Using comet assay diﬀerent PPI glycodendrimers G3 have been
characterized and checked in terms of genotoxicity. As expected,
open shell and dense shell PPI glycodendrimers showed weakest
cytotoxicity towards peripheral blood mononuclear cells (PBMCs)
due to the surface modification of PPI G3. However the most
important finding was the lack of influence of the modification
degree of the analyzed dendrimers on the DNA damage. Even
substitution of approximately 40% amino-terminal groups by
maltotriose residues already significantly reduced cytotoxicity
of PPI dendrimers and highly limited their genotoxicity. The
dense shell PPI glycodendrimer was nontoxic in the whole tested
concentration range (0.05–5 mg mL1), whereas the open shell
PPI glycodendrimer in the same concentration range induced
slight increase of PBMCs cell viability, particularly for the
highest concentration. The distributions of PBMC cells exposed
to PPI glycodendrimers according to their DNA damage (% DNA
in comet tail) was studied using the alkaline version of the
comet assay. Open shell and dense shell PPI glycodendrimers at
the concentration of 0.5 mgmL1 increased the comet fractions
of damaged DNA up to 3.98 and 3.35% accordingly, in respect to
the 2% DNA damage level observed in untreated control cells.
For comparison unmodified amino-terminated PPI dendrimers
caused 10.7%DNA damage level. Both unmodified andmodified
PPI dendrimers revealed an influence on nucleus DNA. However,
due to positive surface charge, the influence of amino-terminated
and open shell PPI dendrimers was the strongest. The increase
of DNA damage in the comet tail can be interpreted as a result
of induction of DNA single-strand breaks caused by these
dendrimers and/or as the formation of abasic sites, which
can be transformed into strand breaks in the alkaline comet
assay. The increase of DNA condensation in the comet head
observed for unmodified and open shell PPI dendrimers might
be due to strong binding of these dendrimers to DNA. This
observation correlates well with the results described earlier:
both, the increase of the DNA level in the comet tail and DNA
condensation in the comet head, are believed to be an effect of
DNA strands wrapping around the PPI dendrimer molecule; and
DNA condensation preventing its repair might lead to cell death.203
Despite this, the revealed small amount of damaged DNA leakage
from the comet head and relatively high cell mortality caused by
amino-terminated PPI dendrimers indicated that genotoxicity does
not seem to be the main reason of PBMC cell death.
Previously described studies have demonstrated that maltose
and maltotriose modification significantly reduced toxicity within
the series of PPI dendrimers. The unique property of higher
cytotoxicity towards to the moderately doxorubicin and cisplatin
resistant human ovarian carcinoma SKOV3 cell line in compar-
ison to the Chinese hamster ovary CHO cell line which does not
demonstrate resistance to majority of anticancer agents, made
these dendrimers per se potentially interesting for an anticancer
therapy.204 Thus, a preliminary evaluation of the clinical value of
treating cells of chronic lymphocytic leukemia (CLL) patients with
G3 unmodified amino-terminated andmaltotriose-modified dense
shell PPI dendrimers was carried out. Finding an explanation
for the selective toxicity of PPI glycodendrimers towards to cancer
cells was essential. Knowing that DNA damage probably is not the
main reason leading to PBMCs cells death, an additional study
was performed to examine the ability of PPI glycodendrimers
to induce changes in mitochondrial membrane potential and
apoptotic cell death. Peripheral blood mononuclear cells (PBMCs)
collected from untreated CLL patients and healthy donors were
used for an in vitro study.204 Chronic lymphocytic leukemia (CLL)
was selected since it is the most common leukemia in Europe and
North America that usually aﬀects people over 60, but recently is
more frequently observed also among younger people. Prognosis
of survival time and the course of the disease depend on the type
of leukemia. In order to achieve prolonged life of the patients
more eﬀective medicines with fewer side eﬀects are sought. Lower
cytotoxicity of the PPI glycodendrimer against normal cells and
higher against leukemic cancer cells in the concentration range
4–10mgmL1 has been demonstrated (Fig. 12). The 24 and 48 hour
incubation of leukemic cells with unmodified and modified
PPI dendrimers resulted in an increasing number of apoptotic
cells along with the higher concentration of the dendrimer and
was significantly higher than the percentage of spontaneous
apoptotic leukemic cells. Interestingly, the dense shell PPI
glycodendrimer (Fig. 12: PPI-DS-Mal-III G3) after 48 hours of
incubation induced apoptosis, which is more pronounced than the
unmodified PPI dendrimer. The IC50 data confirmed apoptotic
action of both analyzed dendrimers which exert significant
inhibitory effects on the viability of leukemic cells (Fig. 12). After
48 hour incubation, concentrations of 0.15 and 10 mg mL1 of
the unmodified and dense shell PPI dendrimer, respectively, were
sufficient to evaluate the IC50 value, while for normal cells the
IC50 value was the same for the unmodified PPI dendrimer and due
to low toxicity it was impossible to calculate IC50 for the modified
glycodendrimer. The presented results distinctly indicated that
the surface modification of PPI G3 dendrimers clearly makes
Fig. 12 Selective apoptosis of CLL cells and no apoptosis of PBMC control
cells by using PPI glycodendrimers in opposite to pure PPI dendrimers which
are toxic against normal and cancer cell lines. Reproduced with permission
from ‘‘I. Franiak-Pietryga, E. Ziolkowska, B. Ziemba, D. Appelhans, B. Voit,
M. Szewczyk, J. Gora-Tybor, T. Robak, B. Klajnert and M. Bryszewska,
Mol. Pharmaceutics, 2013, 10, 2490–2501’’. Copyright 2013 American
Chemical Society.
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glycodendrimers much more suitable for biomedical applica-
tions than unmodified PPI G3 dendrimers.
Substitution of terminal amino groups by maltose was another
method used for PPI dendrimer modification.178 Dendritic poly-
mers functionalized with the disaccharide maltose, similar to
those functionalized with the maltotriose, are non-toxic against
normal cells and toxic to several cancer cell lines. Five types of the
PPI G3 dendrimers were used: unmodified, maltose-modified open
and dense shell and maltotriose-modified open and dense shell.
Research was carried out on peripheral blood mononuclear cells
(PBMCs) collected from healthy donors and three cancer cell lines:
CEM-SS (human T4-lymphoblastoid), U87 (human astroglioma)
and MEC1 (B-chronic lymphocytic leukemia). Maltose-modified
PPI dendrimers were characterized by lack of toxic activity against
normal PBMCs cells, similar to the maltotriose-modified dendri-
mers, and possessed higher toxicity against all three cancer cell
lines: CEM-SS, U87 and MEC1. Among the analyzed glycodendri-
mers, the maltose-modified open shell PPI dendrimer was the most
toxic. Moreovermaltotriose- andmaltose-modified PPI dendrimers
not only reduced cancer cell viability but also induced apoptosis
and inhibited their proliferation.
Mechanism of cytotoxicity of unmodified PPI dendrimers is
believed to be related to the generation of reactive oxygen species
and damage of the mitochondria leading to the cell death due to
apoptosis. The obtained results allow us to presume that the
mechanism of action and interaction of maltose- and maltotriose-
modified dendrimers with the cancer cells might be similar. This
observation correlates well with the results described earlier on
the mechanism of the toxic eﬀect of PAMAM and PPI dendrimers
on human macrophages at the molecular level.205,206
Therefore, identification and understanding of molecular
mechanisms of action of glycodendrimers in a tumor cellular
environment is so critical especially when their application in
antitumor strategies or as diagnostic agents is considered.
Toxicity and mechanism of action of two fluorescently labeled
open and dense shell PPI-Mal G4 glycodendrimers were tested
on several melanoma cell lines (MJS, SK28 and A375).207
Cutaneous melanoma was chosen as one of the most aggressive
types of cancer. Prognosis of 5 year survival time depends on the
stage of disease and represents 50% for patients with lymph node
involvement and 10–20% for patients with distant metastases.
The dense shell maltose-modified PPI glycodendrimer was found
to internalize in the three different melanoma cell lines more
efficiently than in normal cells. Although the viability of cells
exposed to increasing concentrations of this glycodendrimer was
not lower than 90% up to the concentration of 64 mM. The overall
finding was that in all three cancer cell lines glycodendrimers
used more than one pathway for their internalization and there
was a specific pattern of these pathways for each glycodendrimer
in each cell line. For example, only 38% of dense shell glycoden-
drimer internalized via the non-conventional (non-clathrin, non-
cholesterol) pathways in MJS cells, while in SK28 cells 100% of
this dendrimer entered as a result of these mechanisms of
internalization. The cholesterol-dependent route was found to
be the major internalization pathway for open shell glycoden-
drimer in primary melanoma MJS cells. The most important
finding of this study is in fact that PPI glycodendrimers
immediately are endocytozed in all cancer lines and are able
to cross the cell membrane.
Toxicity in vivo
Most studies of biological properties of PPI glycodendrimers
were performed in vitro, and only a few studies have been
carried out in vivo. One of them is particularly dedicated to the
toxicity of three types of PPI G3 dendrimers: unmodified, open
and dense shellmaltotriose-modified dendrimers in rats.208 The
PPI dendrimers demonstrated dose- and sugar-modification-
degree dependent toxicity. As predicted, surface modification
results in lowering or completely suppressing the toxic eﬀect of
the dendrimer’s terminal amino groups, similar to that observed
as previously in the case of in vitro studies. A higher dose of
unmodified PPI dendrimer caused toxicity, whereas sugar-
modified dendrimers revealed minor or lack of toxicity in vivo
under any studied concentration. During the animal study,
body weight, food and water consumption and urine excretion
were analyzed daily. On the 4th, 11th, 25th and 40th day of
the experiment, blood from rats was collected to investigate
biochemical and hematological parameters such as glucose,
creatinine, alanine aminotransferase (AlAT), aspartate amino-
transferase (AspAT), amylase, uric acid (UA), white blood cells
(WBCs), red blood cells (RBCs), hemoglobin (HGB), hematocrit
(HCT), platelets and many others. The condition of the animals
was monitored regularly. The open field locomotor activity test was
performed on the 4th, 11th, 25th and 40th day of the experiment.
In the first experiment, all analyzed dendrimers were orally admini-
stered at diﬀerent doses (1 and 4 mg per kg body weight (b.w.)
per day) for 10 days. In the second experiment, glycodendrimers
were administered also at a higher dose of 16 mg per kg b.w. per
day, whereas unmodified PPI dendrimers, due to their toxicity,
were kept at a dose of 4 mg per kg b.w. per day, also for 10 days.
Then the treatment was followed by a 30 day recovery period
without dendrimer administration.
Unmodified PPI dendrimers caused not only changes in the
behavior of rats, like a decrease in food and water consumption
and lower body weight gain, but also deviation from the standards
in hematological and biochemical profiles. However, all distur-
bances returned to normal levels during the recovery period. Also
the side eﬀects observed during treatment with higher doses of the
open shell glycodendrimer were not permanent. Probably, this
recovery was due to the fact that the dendrimers were excreted via
the renal system and did not accumulate in the body for long time.
Similar to this in vivo study other in vivo results obtained from
open shell G4 (Fig. 7), i.v. administration of mannose- and
lactose-modified PPI dendrimers to mice, also indicated that
the analyzed nanoparticles accumulated in liver, pancreas, heart,
and kidneys but only for a certain length of time and they did not
aﬀect these organs by causing irreversible damages or their
malfunction.209 Importantly, the unmodified PPI dendrimer at
4 mg per kg b.w. per day dose was four times more toxic to rats
than the open shell glycodendrimer at the same dose, whereas
the dense shell glycodendrimer was harmless to animals.208 One
more time it has been confirmed that surface glyco modification
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reduces toxicity of the amino-terminated PPI dendrimer, even if
only approximately 25% of the amino groups are substituted by
maltotriose residues.
As a continuation of the studies on the in vivo eﬀect of
unmodified and maltotriose-modified PPI dendrimers, an
endogenous level of histamine and spermidine, representatives
of biogenic amines and polyamines, upon dendrimer adminis-
tration has been checked.210 Biogenic amines and polyamines
participate in all vital system functions and their levels are impor-
tant determinants of an organism’s condition. Both biogenic
amines and polyamines are called local hormones and play a
major role in the organism, as they influence all their activities.
Histamine is a neurotransmitter but it also plays a crucial
role in inflammation processes and in immune responses.
Polyamines are involved in cell growth or diﬀerentiation. There-
fore, even small changes in the level of amines and polyamines
are a factor for adverse action of the analyzed compound. It
has been checked whether repeated administration of PPI G3,
PPI-OS-Mal-III G3, and PPI-DS-Mal-III G3 influences the endo-
genous level of spermidine, a natural derivative of diaminobutane,
and histamine. All analyzed dendrimers were administered at a
dose of 4 mg per kg body weight per day for 10 days. Column
chromatography on Cellex P, followed by spectrofluorimetric
assays of o-phthaldialdehyde-amine condensation products, was
employed to analyze tissue spermidine and histamine levels
outside the central nervous system, while a radioenzymatic assay
was used to measure the histamine level in the brain. A change
in histamine concentration, which increased over five times
in the small intestine in rats administrated with unmodified
PPI dendrimers was most evident, whereas for the modified
glycodendrimers all values were similar to the control ones.
This enormous increase of the histamine level in small intestine
may indicate rapidly developing inflammatory response with
infiltration of mast cells and other histamine producing cells
caused by the toxic unmodified PPI dendrimer.211 Moreover, this
result is in agreement with the observation of high increase of
leukocytes found in the unmodified PPI dendrimer-treated
rats.208 The level of histamine in the brain decreased only
approximately 10% in the case of all analyzed dendrimers. Also
changes in spermidine concentration were less distinct than for
histamine. Summarizing, a higher dose of the unmodified PPI
dendrimer caused changes in biogenic amines content whereas
sugar-modified dendrimers revealed minor or lack of influence
on the biogenic amine level. Therefore these studies confirmed
that the surface glyco-modification significantly reduces toxicity
and side eﬀects of in vivo administration of PPI dendrimers.
Additionally, a comparative biodistribution of radiolabelled
open shell PPI-OS-Man G4 and PPI-OS-Lac G4, i.v. administrated
to female Balb mice, was carried out to evaluate the selective
targeting properties of these specific Man- and Gal-containing
dendritic glycoconjugates to the liver and lung tissues. Both
glycodendrimers were preferentially accumulated in the liver where
PPI-OS-Lac, containing the terminal Gal units, showed a slightly
higher accumulation rate (B30% after 6 h) than PPI-OS-Man G4
(B22% after 6 h). In contrast to this, PPI-OS-Man G4 also
accumulated in the kidney with a level ofB22% after 6 h, while
the larger and high-molecular weight PPI-OS-Lac G4 is only
nominally captured in the kidney (3.5% after 6 h). Surprisingly,
Gal-containing PPI-OS-Lac G4 outlined no real accumulation in
the lung (o1%). Accumulation of both glycodendrimers in the
liver is explainable by the presence of lectin receptors on the
membrane surface of the liver. This biodistribution study also
shows us that the requested cyclic conformation of Gal unit in
the glycodendrimer PPI-OS-Lac G4 is not a guarantee for a
successful selective targeting to the tissue lung. Other unknown
(biological) key features of PPI-OS-Lac G4 have to be fulfilled to
overcome the biological barrier of lung cells. Finally, the
biodistribution study revealed that Man- and Gal-containing
dendritic glycoconjugates are usable for selective liver targeting,
while naked PPI G4 is preferentially accumulated in the kidney.209
In vivo studies with hyperbranched PEI grafted with oligo-
saccharides maltose or maltotriose at various degrees (OM-PEIs)
are another interesting example of surface modification influen-
cing biocompatibility and changes in pharmacokinetic proper-
ties of dendritic macromolecules.56 Overall survival and animal
welfare, hepatotoxicity, immune stimulation, erythrocyte aggre-
gation, and the eﬃcacy of DNA delivery in vivo were analyzed.
In the experiment, all analyzed polymers were administered
at diﬀerent doses (10, 30 and 100 mg per injection) for 24 and
72 hours to mice. Repeated treatment with higher-degree
oligomaltose-grafted PEI (in opposite to non-grafted polymers)
caused no weight loss but also reduced lethality and, as it was
assessed by serum levels of liver enzymes, eliminated hepato-
toxicity. The partially maltotriose-grafted PEI or PEI-based DNA
complexes demonstrated dose- and sugar-modification-degree
dependent immunostimulatory eﬀects (TNF-a, IFN-g) and erythro-
cyte aggregation. In vivo transfection experiments revealed a
strong dependence of the OM-PEI architecture on DNA delivery.
Summarizing, diﬀerent patterns of maltose- or maltotriose-
grafting on hyperbranched PEI, similar to sugar-modification
of PPI dendrimers, also improve both biocompatibility and
in vivo eﬃcacy.
Crossing blood–brain-barrier
The biological properties in vivo are closely related to the issue of
crossing blood–brain-barrier (BBB). Previous studies have shown
the ability of glycodendrimers to cross various biobarriers, namely,
PPI glycodendrimers were immediately endocytosed in studied
cancer lines and were able to cross cell membranes.207 In addition,
PPI glycodendrimers showed selective toxicity against cancer
cells.178,198,204 Therefore, the combination of successful crossing of
BBB and being potential therapeutic agents would give the chance to
develop new therapeutics for brain diseases. A selective BBB is
composed principally of specialized capillary endothelial cells fitted
with highly restrictive tight junctions. This prevents the passage of
therapeutic particles from the blood to the central nervous system
(CNS). There are however pathways and mechanism for nano-
particles to cross the BBB that rely on the large surface area of
the lipid membranes of the endothelium, transport proteins
(carriers), specific receptor- or adsorptive-mediated endocytosis
and transcytosis. Nevertheless, most drugs for brain diseases
enter the brain via endothelium by adsorptive transcytosis.212
Review Article Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
D
ec
em
be
r 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
3/
05
/2
01
5 
14
:2
5:
23
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2014 Chem. Soc. Rev.
Therefore, the next study was devoted to the analysis of the
biodistribution of fluorescein-conjugated PPI-OS-Mal-III G3
and PPI-DS-Mal-III G3 in rats and its ability to cross BBB.213
Dendrimers were administrated intraperitoneally once a day,
throughout ten days. The dendrimers administrated have shown to
be able to enter rat’s important organs; moreover their tissue
concentration was organ and shell type dependent. The highest
amounts of both glycodendrimers were found in liver and kidneys.
Accumulation in those tissues after repeated administration was
observed despite the fact that three hours after the last injection
both dendrimers have not been observed in blood plasma. Agashe
et al. also demonstrated that the PPI-OS-Man G4 and PPI-OS-Lac G4
glycodendrimers accumulated in mice’s liver and kidneys.209
Quantity of PPI-OS-Mal-III G3 and PPI-DS-Mal-III G3 den-
drimers in other tissues did not exceed 4% of a single dose
administered to rats, probably due to the rapid excretion by the
kidneys. The most important finding of this study was the ability
of analyzed glycodendrimers to cross the BBB and to diﬀuse into
the brain. The other prominent result was that cationic open shell
PPI glycodendrimer PPI-OS-Mal-III G3 penetrated BBB easier
than the PPI dendrimer with neutral dense shell structure (PPI-
DS-Mal-III G3). The authors proposed that both glycodendrimers
entered the brain via the mechanism of adsorptive transcytosis,
which is in good agreement with results obtained by Ku et al.214
PEGylated PAMAM conjugated with fluorescein-doped magnetic
silica nanoparticles also penetrated the BBB by the transcytosis
of vascular endothelial cells in the absence of destruction by
loosening of the endothelial junction or by dissolving the
endothelial membrane. Additional TEM study confirmed that
the endothelial junctions were still compact and the endothelial
membrane was intact.214
In summary PPI glycodendrimers demonstrated the desired
low in vitro toxicity109,178,198,199,204,207 and high in vivo biocom-
patibility.208,210,213 Other dendritic glycopolymers based on
PAMAM, Lys or PEI also outlined low in vitro toxicity as found
in the case of PPI glycodendrimers. Therefore dendritic glyco-
polymers based on dendritic polyamine scaﬀolds can be used
as nanomaterials in biomedical applications, since they show a
similar strong interaction profile than their cationic dendritic
polyamine scaﬀold but exhibit a much superior biocompatibility.
Preferentially their use as a drug delivery system is of high promise,
but it will be also interesting to search for other biomedical
applications of dendritic glycopolymers in diverse areas such as
active compounds in neurodegenerative disorders and inflamma-
tory processes, or for achieving antimicrobial activity.
6. Eﬀects of dendritic glycopolymers
in neurodegenerative disease
Prion diseases are fatal neurodegenerative disorders that occur
in a variety of mammals. In humans they include Creutzfeldt–
Jakob disease (CJD), variant Creutzfeldt–Jakob disease (vCJD), fatal
familial insomnia, Gerstmann–Stra¨ussler–Scheinker syndrome,
and kuru disease. The diseases occur after conversion of cellular
prion protein (PrPC) into a pathogenic, infectious form (PrPSc).
PrPSc self-propagates and it aggregates into amyloids. The
process leads to rapid neuronal loss and eventually death.
Currently no therapy for prion diseases exists. There are how-
ever unceasing attempts to find a compound that would be an
effective therapeutic agent. Preventing the conversion of PrPC
into PrPSc and clearance of PrPSc are two basic therapeutic
strategies that are considered. Dendrimers join in a group of
compounds that are potentially promising in curing prion
disorders. Superfect, a commercially available dendritic struc-
ture used as a transfection agent, cleared PrPSc forms in infected
neuroblastoma cells.215 This finding motivated further tests of
other types of dendrimers. Cationic dendrimers (PAMAM and
PPI) were the most potent, whereas neutral hydroxy-terminated
PAMAM dendrimers had only minor effects. Therefore electro-
static interactions between charged amino acids and charged
surface groups were postulated to be the main forces of these
interactions. The same dendrimers, which effectively cleared
PrPSc, were known previously from interacting strongly with
other proteins.216 Since maltose-coated PPI dendrimers have
shown to maintain the ability to interact with proteins, further
investigations focused on their influence on the process of fibril
formation by a prion peptide PrP 185–208. Fibrillation of this
peptide was chosen as a model of the amyloidogenic process.
It was demonstrated that PPI-DS-Mal G1, PPI-DS-Mal G2, and
PPI-DS-Mal G3 at higher concentrations prevented fibril for-
mation. On the contrary, lower concentrations accelerated the
fibril formation process. The proposed mechanism is that
dendrimers break the formed fibrils in a different way depend-
ing on the concentration. If the process of breakage runs slowly,
as in the case of low doses of maltose-modified PPI, new ends
can be created, which are then extended and form new fibrils.
On the other hand, when the breakage of fibrils is fast, as it
is in the case of high concentrations of dendrimers, all fibrils
are destroyed to monomers. The last process is obviously
desirable.109 However, speeding up the process of fibril formation
can also have a protective effect, since short fragments, called
protofibrils, were shown to be most toxic.217 Other possible
mechanisms of fibril formation inhibition involve binding of
peptide monomers or blocking of fibril ends by dendrimers
which prevents fibril extension (Fig. 13). The mechanism
of breaking fibrils by sugar-modified dendrimers (PPI-DS-Mal
G4 and PPI-DS-Mal III G4) was further confirmed by EPR
studies.112 Performing experiments, that were analogous to
the first attempts by Supattapone et al.,215 was the next logical
step in studying neutral PPI glycodendrimers. It turned out that
the sugar modification of the surface groups did not abolish the
antiprion activity. PPI-DS-Mal G2, PPI-DS-Mal G3, PPI-OS-Mal
G4, PPI-DS-Mal G4, and PPI-DS-Mal-III G4 effectively reduced
the level of PrPSc in infected ScN2a cells.110 Moreover they
cleared the pre-existing aggregates in homogenates from
infected mice brains. It has been postulated that dendrimers
mediate in the denaturation of PrPSc. Elimination of PrPSc from
brain homogenates was earlier observed e.g. for cationic phos-
phorus dendrimers,218 but the finding that cationic surface
groups are not essential for anti-prion activity is important
from the toxicological point of view. It has been demonstrated
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that not only cationic polymers, but also non-toxic glycoden-
drimers can inhibit the prion infection. However, each type of
dendrimers reduces PrPSc in a prion strain dependent manner.
Dendrimers with cationic surface groups (PPI G3, PAMAM G5
and PPI-OS-Mal G4) are more potent against a wider range of
prion strains than PPI-DS-Mal G4.113 Strain-specific properties
are probably governed by PrPSc conformation and the glycosyla-
tion pattern that differs between strains. It makes dendrimers a
potential diagnostic tool in differentiating between protein
strains (Fig. 14). Interestingly, anionic glycodendrimers with
sulfate groups on the surface are also able to reduce the level of
PrPSc in a prion strain-dependent manner.114 Here, cationic
dendrimers may interact with negatively charged groups of
PrPSc, while anionic dendrimers can interact with pockets of
cationic charges. Earlier similar phenomena were found for the
interactions of bovine serum albumin with anionic and cationic
PAMAM dendrimers.219 It seems that the density of surface
groups is more important than the charge. The ability to interact
with PrPSc increases when the surface groups are densely packed.
McCarthy et al. explored in a detailed manner the mechanism of
anti-prion activity of PPI-DS-Mal G4.115 This dendrimer inhibits
conversion from PrPC to PrPSc in dendrimer-pre-treated prion
strains infected N2a cells. Several pathways can be involved in
this: interfering with short-lived intermediates of the conversion,
disturbing PrPSc trafficking, and altering PrPSc structure so it is
not capable to initiate PrPC misfolding. Interestingly, PPI-DS-Mal
G4 does not interact directly with PrPC within the cells. This is
considered to be a positive result, since the PrPC role is not fully
understood yet, so no detectable effect on PrPC means that the
dendrimer can stop formation of PrPSc with minimum toxicity
to the cell.116
The therapeutic potential of dendrimers is not limited to prion
diseases. Dendrimers have been shown to possess an in vitro
Fig. 13 Three main mechanisms of possible anti-amyloid activity of den-
drimers: (A) interaction with peptide monomer, (B) blocking fibril ends,
(C) breaking fibrils. Chemical structure of the PrP 185–208 peptide is shown
in the frame (grey spheres are the dendrimers).109 The disaggregation
process is strongly depending on the molar ratio of amyloidogenic peptide
and PPI glycodendrimer to fabricate different morphologies of aggregates
(Fig. 15). Reproduced from ref. 109 with permission from Wiley-VCH.
Fig. 14 Diﬀerentiation of prion strains – immunoblot images of dendrimer treated brain homogenates were analyzed by densitometry for % PrPres levels
which remained after dendrimer treatment and protease digestion, calculated relative to a non dendrimer treated control. Legend: 79A; RML;
ME7; 301V; 301C; 22A. Error bars represent SD; n = 2 biological repeats. * Statistically significant difference between prion strains at the
concentrations indicated (po 0.01). Themean levels of PrPres remaining for each prion strain after treatment with 72 mM PPI-DS-Mal G4, 114 mMPPI G3, 14 mM
PAMAM G5 or 54 mM PPI-OS-Mal G4 were compared using a one-way ANOVA. Prion strains 79A, RML, 301V and 301C can be statistically differentiated. 22A
and ME7 can be differentiated from the other prion strains but not from one another. Reproduced from ref. 113 with permission from Wiley-VCH.
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eﬀect on Ab peptides. These peptides are the main components
of fibrillar amyloid plaques found in brains of individuals
suﬀering from Alzheimer’s disease. Various dendrimers (PAMAM,
PPI, phosphorus) inhibited in vitro fibrilization of a fragment
of Ab (Ab(1-28)) and reduced toxicity caused by intermediate
oligomeric species.188,220,221 PPI-DS-Mal G3 and PPI-DS-Mal G4
dendrimers were proved to interfere with the fibrillization of
Ab(1-40). However, the mode of the action was generation-
dependent.111 PPI-DS-Mal G4 blocked fibril formation by generating
amorphous aggregates, whereas PPI-DS-Mal G3 generated clumped
fibrils (Fig. 15). These two modes of the action had serious
consequences on the toxicity of the final product. Amorphous
aggregates were found to be toxic, while clumped fibrils are
non-toxic.
The first and till now only in vivo study that reported both the
phenomena of crossing the blood-brain-barrier and potential
applicability of PPI glycodendrimers as candidates for antiamylo-
idogenic agents was done by Klementieva et al.118 They used a
wide panel of glycodendrimers: PPI-DS-Mal G3, PPI-DS-Mal G4,
PPI-OS-Mal G3, and PPI-OS-Mal-III G3. Influence of analyzed
glycodendrimers on the cytotoxicity induced by Ab(1-42) and
human brain extracted Ab peptides was tested in a human
neuroblastoma cell line (SH-SY5Y). In the animal study dendri-
mers were administrated once a day, for five or ten days in the
case of short term experiments and for one month in the case of
a long-term experiment, in doses of 10mg per kg b.w per day and
1 mg per kg b.w per day of open and dense shell glycodendrimers,
respectively. As expected maltose-modified PPI dendrimers were
able to reduce the toxicity of Ab(1-42). Nevertheless, only dense
shell maltose-modified dendrimers of both generations reduced
the toxicity of Alzheimer’s disease brain extracts in SH-SY5Y
neuroblastoma cells. Moreover, at low concentrations those
dendrimers possessed capacity to accelerate Ab(1-42) peptide
fibril formation. The analyzed glycodendrimers were able to
cross not only cell membranes, but also the BBB. Moreover, both
open and dense shell maltose-modified PPI glycodendrimers were
able to modify the Ab profile of APP/PS1 mice (rodent model of
Alzheimer’s disease). The open shell PPI glycodendrimer was
found to be harmful for mice under chronic administration and
caused cognitive decline in nontransgenic mice, while dense shell
PPI glycodendrimers revealed positive eﬀects which will promote
further studies with these dense shell entities in the future.
7. Dendritic glycopolymers as drug
delivery systems
Nowadays dendritic polymers are one of the promising and
tunable nanomaterials222–226 for therapeutics and diagnostics.
Especially, the advantageous (physicochemical) key features of
dendritic polymers in drug delivery are well documented in
several papers.222,223,226–230 Some specific features of dendrimers
that make them highly attractive for in vitro and in vivo delivery of
drugs are: tunable surface charges,231 ability to cross biological
barriers,232–235 high water-solubility, ability to enhance solubility
of poorly water-soluble drugs,232 high loading capacity of drugs,223
stability and biocompatibility and tailored and fine-tuned
pharmacokinetics and pharmacodynamics achieved by a suita-
ble design of the molecular architectures.236–239 Further specific
dendrimer features for successful biological actions are nano-
sized dimensions suitable for the EPR effect (enhanced perme-
ability and retention effect) along leaky blood vessel, e.g., to
accumulate in tumors = passive targeting,223,226 active targeting
Fig. 15 Transmission electron micrographs of: Ab(1-40) incubated at pH
7.4 (coexistence of fibrils and globular oligomers) (A); Ab(1-40) icubated at
pH 7.4 in the presence of minor PPI-DS-Mal G3 (detection of clumped
fibrils) (B); Ab(1-40) incubated at pH 7.4 in the presence of PPI-DS-Mal G4
(dendrimer–peptide ratio 1, detection of granular non-fibrilar, amorphous
aggregates) (C). Ab(1-40) and Ab(1-40)–dendrimer complexes were incubated
for 12 hours at pH 7.4 and 37 1C before the preparation of the microscopy
grids. Reproduced with permission from ‘‘O. Klementieva, N. Benseny-Cases,
A. Gella, D. Appelhans, B. Voit and J. Cladera, Biomacromolecules, 2011, 12,
3903–3909’’. Copyright 2011 American Chemical Society.
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capability by introducing ligand for interacting with over-
expressed receptor targets,232,240–243 possibility of different kind of
administration forms,244 minimizing drug’s degradability,222,244
and others. Overall, the molecular composition inside and outside
of the dendritic scaffold and the huge number of functional surface
groups of dendritic polymers are mainly responsible for their
physicochemical and biological features.
Recent progress in dendritic glycopolymers as drug delivery
systems will be briefly highlighted here. But firstly the general
complexation/interaction properties of dendritic glycopolymers
against various analyte and drug molecules are viewed to get
further insight into the structure–property relationship of dendritic
glycopolymers based on dendritic polyamine scaffolds.
Generally, the interaction and complexation pro-
perties of (oligo-)saccharide-modified dendritic poly-
amines10,54–59,62–75,76–78,84,89,91,92,109,181–183 are mainly tailored
by their pH-dependent cationic (surface) charges to undergo
ionic interactions with various anionic low- and high-molecular
weight drugs (e.g. dye molecules, ATP, si-RNA, DNA). Here, two
tendencies are recognizable. Dendritic glycopolymers based on
PAMAM dendrimers and PEI scaffolds are preferentially used
for the formation of (defined) polyplexes using various RNA and
DNA macromolecules,54–59,62–75,89,91,92 while dendritic glyco-
architectures based on PPI dendrimers are mainly used for the
complexation of (non-)charged low-molecular weight analytes
and drugs.77–84,109,183,245
Complexation and interaction of dendritic glycopolymers with
low-molecular weight compounds
A closer view on the complexation properties of PPI glycoden-
drimers outlines the following issues. First, dense shell PPI
glycodendrimers possess very limited ionic interaction proper-
ties against small anionic analytes.109,183,245 Thus, a low number
of ANS molecules can be complexed by PPI glycodendrimers,109
while ATP and Mant-ATP molecules do not undergo any inter-
actions with these dendritic glycoarchitectures (Fig. 11).246 These
anionic nucleic acids are too bulky to drain the dense shell of PPI
dendrimers in comparison to smaller anionic ANS molecules.
In contrast to this, very small anionic Re clusters (r1 nm) are
complexed by dense shell PPI glycodendrimers.247 Second, cationic
open shell PPI glycodendrimers are able to complex anionic nucleic
acids, ATP, ADP, AMP, fludarabine and Mant-ATP, at various
conditions, and form stable complexes.183,245 Therefore, com-
plexation of the nucleic acids mainly depends on pH and NaCl
content.183,245 Complexes with ATP are not degradable by alkaline
phosphatase, when using G4 of the PPI glycodendrimer.245 The
open shell in PPI glycodendrimers has here the function of a
protective shell in the presence of enzymes.
Finally, the group of Jain focused on the complexation and
interaction of (very) hydrophobic and less water-soluble drugs
where ionic interactions of open shell PPI glycodendrimers78,84
play a minor role (Fig. 16).78–84 Open shell PPI glycodendrimers
are able to (slightly) increase the complexation of those drugs
caused by the presence of the saccharide shell and to induce a
better sustained release of drugs for several hours or days than
their parental counterparts.78–84 Various surface-modified PPI
dendrimers (shell (partially) decorated with PEG,248,249 lacto-
ferrin,250 polysorbate 80,251 thiamine,252 luteinizing hormone,253
lipoproteins,254 arginine255 or tuftsin as cell-penetrating pep-
tide256) were also successfully tested for sustained release of poor
water-soluble drugs (e.g. doxorubicin, docetaxel, paclitaxel, famo-
tidine, primaquine). Again, the additional surface modification
of PPI dendrimers also induces better shielding/densification
and (partly) back-folding properties of surface groups to explain
sustained release of drugs.248–256 Furthermore, ionic interactions
are in minority248–250 and the formation of partially aggregated
but still under physiological conditions soluble complexes251–255
is responsible for their positive use in biological applications.
Knowing that ionic interactions are the most favorable mole-
cular action of parental PPI dendrimers against drugs,222 while
hydrophobic drugs’ (indomethacin, famotidine, amphotericin B)
complexation by the parental PPI dendrimer are tailored by pH
and functional groups of hydrophobes,257 similar interaction
features for the open shell PPI glycodendrimers (Fig. 7) can be
assumed.78–84 Surprisingly, complexation towards low-molecular
weight compounds of other open shell glycodendrimers, e.g. based
on PAMAM and the Lys dendrimer core, are rarely encountered. The
galactose-modified Lys dendrimer is able to better complex chloro-
quine phosphate than the un-modified Lys dendrimer.258 Similar
complexation behavior for chloroquine phosphate was observed
when polyelectrolyte complexes, consisting of a Lys dendrimer and
anionic chondronitin sulfate, were used.259 Open shell PAMAM
glycodendrimers are also capable of ANS complexation.260
Further insights into the complexation and interaction
properties of core–shell glycoarchitectures, based on PEI cores,
against several vitamins (B1–B3, B6 and B12) and drugs (ATP,
pantoprazole and acid-containing estradiol derivative) were
Fig. 16 Drugs used in in vitro and in vivo studies, stabilized by open shell
PPI glycodendrimer.
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recently obtained in pure water.10,182 In this study it was found
that molecular interactions between core–shell glycoarchitec-
tures and analytes are mainly tailored by the interaction
characteristics of the analytes themselves. These analyte mole-
cules have to match the pronounced ionic interaction charac-
teristics of cationic PEI core–shell structures, otherwise no or
low interactions are present between analyte molecules and the
dendritic glycopolymer.181,182 Thus, moderate and strong inter-
actions are only given when anionic vitamins182 and drugs10,182
(B3, B12, pantoprazole, acid-containing estradiol derivative and
ATP) are mixed with cationic PEI core–shell glycoarchitectures.
Moreover, it was found that open and dense shell glycoarchitec-
ture will facilitate the interaction between anionic analytes and
cationic PEI scaffold compared to the non-modified parental
PEI scaffold, while the glyco shell itself does not contribute to
any preferential kind of molecular interactions (e.g. H-bonds)
against analyte molecules.182 In addition cationic, amphiphilic
and neutral vitamins do not undergo any significant interactions
with cationic PEI core–shell glycoarchitectures.
Generally, dendritic glycopolymers stabilize low-molecular-
weight drugs better in various solutions and allow for a more
sustained release compared to the parental dendritic scaﬀolds.
From these results one cannot distinguish between drugs that
are completely encapsulated by dendritic glycoarchitectures as
postulated for other dendritic scaﬀolds222,223 and aggregates
consisting of dendrimer-complexed drugs. In the following the term
‘‘dendritic glycopolymer-stabilized drugs’’ will be used to describe the
glycopolymer drug delivery systems not distinguishing between
drugs located within the dendritic scaﬀold, those located more
in the shell and larger dendrimer/drug aggregates.182,222
Complexation and interaction of dendritic glycopolymers with
high-molecular weight compounds
Parental PPI dendrimers have been shown to interact with
genetic material forming dendriplexes of diﬀerent character-
istics depending on the generation of the dendrimers and the
type of the oligonucleotides. Since one of the potential anti-HIV
treatments is gene therapy, interactions between PPI dendrimers
and anti-HIV oligonucleotides, as well as properties of formed
complexes have been investigated in detail.261 PPI G1, PPI G2
and PPI G3 formed complexes with SREV, ANTI-TAR, and
GEM91 anti-HIV oligonucleotides (ODNs) at diﬀerent molar
ratios as assessed by fluorescence polarization. With increasing
generation number of PPI dendrimers lower amount of PPI
dendrimers is needed to undergo desired formation of stable
complexes with ODNs (e.g. 15–20 of PPI G3 for one ODN). These
differences could result from different sizes and features of
dendrimers (diameters, molecular weight, number of surface
charges, shapes). The most effective binding with PPI dendri-
mers was achieved with SREV, while GEM91 was characterized
by the worst binding efficiency. The lengths of oligonucleotides
do not play a significant role in interactions with dendrimers.
It is, however, likely that nucleotide sequence and the ability
to form secondary structures may have an influence on the
binding efficiency of ODNs with PPI. Zeta potentials of saturated
complexes were slightly negative for PPI G2 and PPI G3 or close
to neutral for PPI G1. It is generally assumed that cationic
compounds permeate cell membrane more efficiently than
neutral or negatively charged compounds.262 Nevertheless, it
is possible that the positive surface charge is not the main
decisive factor of successful internalization and transfection,
since commercially available transfection reagents such as
Lipofectin and Lipofectamine are also characterized by negative
zeta potentials. Hydrodynamic diameters for all measured
PPI complexes amounted to approximately 250 nm, which is
an appropriate size for transfection. Studies on dendriplexes
morphology using TEM revealed the presence of big aggregates
(even up to 800 nm), which may, however, be a result of a
sample preparation procedure.261
Dendriplexes, composed of the same ODNs and open shell
PPI G3 dendrimers modified with maltose (PPI-OS-Mal G3) and
maltotriose (PPI-OS-Mal-III G3), have also been examined. In this
case one molecule of ODNs bound 4–5 molecules of dendrimers.
These dendriplexes were also shown to be stable for more than
20 hours. The hydrodynamic diameter of dendrimers alone was
5.7 and 6 nm for PPI-OS-Mal G3 and PPI-OS-Mal-III G3, respec-
tively. The biggest dendriplexes were formed by both dendrimers
with SREV and PPI-Mal G3 with AT and GEM91 (150–200 nm).
PPI-Mal-III G3 with AT and GEM91 generated smaller structures
of a diameter of 50–100 nm. The size of complexes was inde-
pendent of the length of ODNs and relayed to a minor degree
on the dendrimer :ODNs molar ratio. The zeta potential after
addition of dendrimers increased from about 24 mV to about
(18) to (14) mV for all tested complexes. Detailed analysis of
the morphology of dendriplexes revealed that PPI-OS-Mal G3 and
PPI-OS-Mal-III G3 form rod-like structures in complex with
GEM91. It is suggested that these nanorod structures are formed
by a one-directional self-assembling process. On the other hand,
PPI-OS-Mal G3/AT dendriplexes existed as monomeric units as
well as long (up to 1 mm) fibrils. Similar results were observed for
PPI-OS-Mal-III G3/AT. Both dendrimers, complexed with SREV,
formed another type of structure, namely, 3D square-like nano-
structures. It is assumed that in this case the self-assembling
process is oriented in three axes. These data correlated with
molecular modelling, corroborating formation of described
nanostructures.263
Drzewinska et al. showed that complexation of all three
ODNs with naked PPI, PPI-OS-Mal G3 and PPI-OS-Mal-III G3
protected the oligonucleotides against nucleases contained
in cell medium FBS. Furthermore, it was demonstrated that
the surface oligosaccharide shell of PPI is necessary for the
prevention of ODN hydrolysis by endonuclease S1. This implies
that the sugar layer surrounding the dendrimer poses additional
‘‘shielding’’ isolating ODNs from endonuclease S1 degradation.
But none of the studied dendrimers protected ODNs against
digestion at low pH (B4.5).264
One of the important aspects of nucleic acids delivery to
cells by dendrimers is their interaction with glucosaminogly-
cans (GAGs). GAGs are components of the extracellular matrix.
Due to their negative charge, they can displace oligonucleotide
cargo from dendriplexes, thus seriously aﬀecting the transfection
process. For this reason, Szewczyk et al.265 studied interactions
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between complexes formed by PPI G3 (naked, maltose- and
maltotriose-modified) and anti-HIV ODNs (AT, SREV and
GEM91) and four GAGs (heparin, heparan sulfate, chondroitin
sulfate, and hyaluronic acid). Addition of heparin, possessing
the highest negative charge of all GAGs, to unmodified PPI–
ODNs complexes had no or only a slight effect up to 10 mg mL1
as assessed by the fluorescence polarization method. Larger
concentrations, however, led to a pronounced decrease in fluores-
cence polarization, down to the value of free ODNs (at the
concentration of 20 mg mL1), indicating a complete dissocia-
tion of complexes. In the case of studied glycodendrimers,
application of heparin resulted in gradual decomposition of
dendriplexes up to the concentration of 2–3 mg mL1. The
different behavior of naked PPI and sugar-modified dendrimers
in the presence of heparin may result from several factors. First,
uncoated PPI, possessing more positive charges, bind ODNs
stronger than the PPI glycodendrimer. Second, maltose and
maltotriose units may affect the interaction properties of the
cationic scaffold in the glycodendrimer, and last, glycodendrimer–
ODNs complexes were formed at lower molar ratios in comparison
to dendriplexes with naked PPI. Heparan sulfate also caused a
progressive decrease in fluorescence polarization (complexes
breakdown) but the value of free ODNs was reached only at
about 500 mg mL1. In contrast to heparin and heparan sulfate,
chondroitin sulfate and hyaluronic acid had no or minor
influence on the stability of tested dendriplexes. These results
were corroborated by electrophoretic mobility studies of ODNs
bound to PPI in the absence and presence of GAGs. The
obtained results indicate that under physiological conditions
only dendriplexes formed by oligosaccharide-modified PPI
and ODNs are destroyed by heparin, while naked PPI–ODNs
complexes are not affected. In future transfection experiments
interaction of dendriplexes with GAGs can lead to effects which
negatively influence the transfection process. First, GAGs can
lead to disassociation of complexes (in the presence of heparin),
which can result in ODNs destruction. Second, GAGs change size
and charge of dendriplexes, which can hamper internalization
and trafficking of complexes. Third, association with GAGs can
modify the intracellular fate of dendriplexes. Thus, finding a
perfect delivery platform is a challenging task. Considering that
sugar-coated dendrimers possess better protective properties
against nucleases and exhibit lower cytotoxicity198,208 than naked
PPI, they can be considered as better candidates for drug delivery
platforms. On the other hand, while naked PPI–ODNs complexes
are unaffected by physiological concentrations of heparin in the
absence of cell medium, glycodendrimer–ODNs complexes
undergo dissociation in the presence of these GAGs.265
Dendritic glycoconjugates for targeted drug delivery
Recent developments are directed to establish a dendritic nano-
carrier with targeting ligands222,223,226,266 to reduce adverse
eﬀects of drugs during treatment. For this purpose various
diﬀerent biological ligands (e.g. folic acid, RGD peptide, various
(oligo-)saccharides, polysorbate 80, methotrexate, lactoferrin,
transferrin, thiamine, antibody and cell-penetrating peptides)
were chemically and biologically connected to various dendritic
scaﬀolds, but also to linear polymers267 and nanoparticles.268
Similarly, also glycosylated carrier conjugates269 with targeting
moieties address all therapeutic applications as known from
non-glycosylated carrier systems (cancer therapy, organ imaging,
photodynamic therapy vaccine delivery and delivery of therapeutic
agents etc.). It was shown that glycosylated nanocarriers are able
to undergo site specific delivery and present an alternative way to
administrate drugs into specific cells and organs.269
Following the above considerations, open shell PPI glycoden-
drimers are the preferential molecular entities to solubilize and
deliver various low molecular-weight drugs to specific biological
entities (cells or organs).78–84 To facilitate the penetration of various
biological barriers, e.g., membranes of cancer cells and macro-
phages, dendritic PPI scaffolds were modified with mannose,
galactose and sialic acids as targeting ligands. The main applica-
tion of the dendrimer-stabilized drugs78,80–84 (Fig. 16) was directed
to prevent infection of human immunodeficiency virus (HIV),80,81,83
malaria,78 and tuberculosis79 or to suppress inflammation
processes,84 for example, in liver.
T-lymphocytes, dendritic cells, monocytes, and macrophages
are the target cells for the general attack of HIV. Monocytes,
macrophages and dendritic cells are generally considered as
depots to distribute the HIV in human, but also, for example,
other viruses. Thus, for the treatment of virus infections any
therapeutic agent has to be administrated to these cells in
addition to other organs like the liver, lung or brain. Contrary
to the anti-adhesive glycodendrimers which block the receptors
of macrophages or dendritic cells for the virus uptake/entrance
(Fig. 2 and 4), the same or other sugar receptors (mannose,
galactose, sialic acid and oligomannose) and further receptors
on macrophages and dendritic cells will be used for the targeted
uptake of dendritic glycopolymer-stabilized anti-HIV drugs
(efavirenz, lamivudine and zidovudine)80,81,83 (Fig. 16). In all cases
better cellular uptake of the drug by dendritic glycopolymer-
stabilized drugs was achieved in comparison to other control
systems (parental PPI dendrimer or other PPI dendrimer deriva-
tives). Furthermore, cell viability of macrophages after the uptake
of dendritic glycopolymer-stabilized drugs was also not impaired
for at least 48 h. Biological activity of the anti-HIV drug lamivudine,
considered in its active triphosphate derivative as a nucleoside
analogue reverse transcriptase inhibitor, was successfully proven
when using the open shell mannose-decorated PPI dendrimer.
In the recent biodistribution study of Gajbhiye et al.83 it was
explicitly shown that only the coincidental decoration of mannose
and sialic acid on the PPI dendrimer surface guarantees an
enhanced accumulation of the anti-HIV drug zidovudine, also
acting as a nucleoside analogue reverse transcriptase inhibitor,
in the lymph node, while the cationic sialic acid- or mannose-
decorated PPI dendrimers outline a reduced uptake of zidovudine
of about one third and less in lymph nodes as found in the cases of
mannose- and sialic acid decorated PPI dendrimers. The motiva-
tion of this study was to show that both mannose and sialic acid
units may induce a dual targeting profile recognized by the sugar
receptors of lymph nodes. Besides this, galactose-78 and fucose-
modified84 PPI dendrimers were successfully used to enhance the
targeting of the organ liver for the administration of the drugs
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primaquine phosphate and sulfasalazine, respectively. This
biological behavior is preferentially achieved by the prolonged
blood circulation of dendritic glycopolymer-stabilized drugs.
However, the previous use of dense shell PPI glycodendri-
mers and PEI glycoarchitectures as a drug delivery system
for low molecular-weight drugs only focused on the delivery of
HIV-derived antigens to immature and mature dendritic cells
(DC).60,61,76,77 The molecular uptake of drugs and carrier
systems into immature and mature DC is hampered by the
biological membrane of DC, while the cellular uptake of small
and larger molecules is still facilitated in the case of mono-
cytes.61 To overcome the non-interacting properties of dense
shell PPI glycodendrimers against ATP molecules246 (Fig. 11)
few PEG-spacered amino groups have been introduced in the
outer shell of the dendritic glycoarchitecture to undergo
the desired electrolyte complexation with anionic HIV-derived
peptides (Nef, Gp160 and P24).77 This forced molecular inter-
action on the cell membrane surface of immature DC allowed
the capturing of anionic peptides in DC when excess of modified
dense shell PPI glycodendrimers was used, while the administra-
tion of pure anionic peptides resulted in a low uptake of those
peptides in DC. A similar concept was used for dense shell PEI
glycoarchitectures.60,61 Here, the conjugation of HIV-derived
peptides was realized by the conjugation of a spacered Ni(II)–
NTA-His6-tag (Fig. 17) where the pH-sensitive conjugation unit
can be smoothly destroyed rpH 6 (ref. 60) to release those
peptides in the endosome or lysosome of DC.61 A similar
molecular uptake mechanism in immature DC was found as in
the case of PEG-spacered amino group modified dense shell PPI
glycodendrimers.77 An excess molar ratio of Ni(II)–NTA modified
dense shell PEI glycoarchitectures against His6-tagged anionic
peptide Gp160 is needed to capture anionic peptide in DC.61
Moreover, both dendritic glycopolymer architectures, upon
being captured in immature DC, do not hamper the maturation
process of immature DC and their migration properties, and
thus, these glycopolymers may be suitable materials for future
DC-based immunotherapy.61,77
Finally, PPI dendrimer conjugated dextran nanomaterials were
successfully used as potential vectors for the delivery of the anti-
cancer agent, doxorubicin hydrochloride, to lung epithelial cancer
cells in vitro.82 Moreover, prolonged blood circulation and
enhanced accumulation in tumor tissues, triggered by the EPR
eﬀect, of nanoparticle-stabilized drug were also determined.82
Summarizing the previously described results, various den-
dritic glycopolymer-stabilized drugs with and without targeting
properties have been established over the last years.77–84 Inter-
estingly, the application of these dendritic glycoconjugates is
mainly directed to address the treatment of infectious diseases
induced by bacteria and viruses.
A future challenge is a better control over the number of
drug molecules in those nanocarriers. This may be solved by
the chemical coupling of drugs, for example, to the dendritic
scaﬀold or to the sugar units. Zhang et al.90 combined several
advantageous strategies in a ligand-mediated drug delivery
system. Besides using a biocompatible dendritic glycopolymer-
conjugated drug material, the drug methotrexate was selectively
conjugated to sugar units via ester bond formation, while the
conjugated drug methotrexate itself also takes over the function
of folic acid enhancing the binding avidity to folate-binding
proteins on the surface of KB cancer cells. The molecular
composition of methotrexate is similar to the folic acid.90 These
dendritic glyco-drug conjugates show the potential as anti-cancer
nanocarriers for the specific targeting and killing of folate
receptor-expressing tumor cells.
Finally, one can state that dendritic glycopolymers, preferen-
tially based on PPI dendrimer cores, are attractive, biocompatible
Fig. 17 Schematic illustration of Ni(II)–NTA-spacered dendritic glycopolymer (Ni(II)–NTA–DGP) interactions with HIV-derived peptide His6-Gp160.
Reproduced with permission from ‘‘N. Hauptmann, M. Pion, R. Wehner, M.-A. Mun˜oz-Ferna´ndez, M. Schmitz, B. Voit and D. Appelhans, Biomacromo-
lecules, 2014, 15, 957–967’’. Copyright 2014 American Chemical Society.
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alternative drug delivery systems with (highly) adaptable prop-
erties against cells and organs in comparison to other surface-
engineered PPI dendrimer nanocarriers.248–256
Dendritic glycoconjugates as targeting non-viral vectors
Some sugar-decorated dendritic polyamine scaﬀolds usable as non-
viral vectors of DNA and RNA are also characterized by selective
targeting properties against cells and organs.54–59,62–75,85–89,90,92
Two dendritic polyamine scaffolds, PAMAM dendrimers and hyper-
branched PEI, have attracted the highest attention in this specific
application field.
A closer view on the work of Arima and Uekama reveals an
impressive interplay of the molecular composition of sugar-
decorated PAMAM dendrimer conjugates with cyclodextrins as
non-viral vectors.85–89,92 The initial work of Roessler et al. showed
the characterization of the interaction of polyplexes (dendrimer/
DNA) in the presence of b-cyclodextrin (b-CD) where b-CD
concentration also affects the physico-chemical properties of
those polyplexes. Moreover, the improvement of in situ transfec-
tion hints to the power of novel dendritic polyamine scaffolds
decorated with different cyclodextrins (a-, b- and g-CD).270 Low
numbers of a-, b- and g-CD attached to the PAMAM dendrimer
surface allowed the enhancement of gene transfection in com-
parison to those of parental PAMAM dendrimers.270 Using 3rd
generation PAMAM dendrimer with 2 a-CD moieties biodistribu-
tion of polyplexes with DNA 12 h after intravenous administra-
tion in mice showed that DNA is efficiently delivered in the
spleen, liver and kidney with negligible changes in blood
composition.271 Especially, higher gene transfection in the
spleen was determined after the administration protocol of
polyplexes (12 h). After an optimization process 2nd generation
PAMAM dendrimer with 2 a-CD moieties proved to be superior
to commercially available TransFastt and Lipofectint for in vitro
and in vivo gene transfection.85,271
Arima and Uekama further fabricated a-CD-G2 and a-CD-G3
hybrid materials additionally decorated withmannose, galactose or
lactose units as targeting ligands in receptor-mediated uptake
processes. To realize mannose receptor-mediated non-viral delivery
systems,86,88 a-D-mannopyranosylphenyl isothiocyanate was used to
synthesize non-viral vectors with increasing numbers of mannose
(up to 8 units) in the outer shell of a-CD-G2 (Man-a-CD-G2).
Surprisingly, with increasing Man units, formation of polyplexes
with Man-a-CD-G2 decreased, while polyplexes with 8 Man units in
Man-a-CD-G2 were enzymatically degraded. Moreover, only a weak
binding ability of Man-a-CD-G2 to the mannose-receptor on the
cell membrane surface was determined despite having partially
enhanced gene transfer activity with increasing Man units in Man-
a-CD-G2. This can be explained by the too short or too rigid spacer
between Man units and the dendritic PAMAM scaﬀold where,
finally, mannose is not recognized by the mannose-receptor binding
proteins under in vitro conditions. Despite the unexpected in vitro
behavior ofMan-a-CD-G2 with about 3.3mannose units, in vivo gene
transfer activity of non-viral vectors 12 h after intravenous injection
to the tail vein of mice was determined. Surprisingly, Man-a-CD-G2
outlined much higher gene transfection compared to the pure 2nd
generation PAMAM dendrimer and a-CD-G2 at 12 h after injection.
In line with this, galactose-decorated a-CD-G2 (Gal-a-CD-G2),
prepared by the conversion of a-CD-G2 with a-D-galactopyrano-
sylphenyl isothiocyanate, were also tested as non-viral vectors
for the treatment of liver diseases.272 As found in the case of
Man-a-CD-G2, Gal-a-CD-G2 showed no selective targeting proper-
ties, meaning no receptor-mediated cellular uptake against
hepatocytic cells, but some gene transfer activity could be
detected under in vitro conditions.272 Further eﬀorts have been
done in this direction by Arima and colleagues.273,274 Dendritic
polyamine scaﬀolds a-CD-G2 and a-CD-G3 were converted with
the lactone of lactose to introduce the desired galactose for under-
going desired asialoglycoprotein receptor-mediated cellular
uptake of polyplexes in vitro and in vivo studies. For this purpose,
only an average binding of 2.6 lactose units on a-CD-G2 was
needed to show hepatocyte-specific gene transfer activity in vivo,
consistent with in vitro transfection results, using HepG2 cells.273
The knowledge gained from these studies may help to develop
more eﬃcient ligand-modified dendritic non-viral vectors with
few a-CD units in the future.
Similarly, eﬀorts have been undertaken to establish targeting
sugar-modified hyperbranched PEI (TSPEI) as non-viral vectors
in gene therapy for better overcoming biological barriers of lung
and liver tissues, but also of dendritic cells, macrophages and
other cells (hepatocyte cells, fibroblast membranes or airway
epithelial cells).62–75 In the field of TSPEI similar observations
were made as found in the case of sugar-decorated PAMAM
dendrimers with a-cyclodextrin units: with increasing degree
of substitution of PEI functional amino groups by sugar units
(e.g. galactose)67 decreasing gene transfer activity was determined.
Second, the presence of targeting sugar units on PEI scaffolds led to
a decreased, the same or partially better transfection efficiency
compared to the parental PEI, depending on the degree of sub-
stitution, but in all cases significantly better biological actions of
the TSPEI were observed.62,66,74
Considering the results from non-targeting sugar-modified
hyperbranched PEI (NTSPEI) as non-viral vectors54–59 similar
results with all their positive and negative facets are also
available as found for TSPEI. In addition, interesting points
of NTSPEI can be extracted from their results. First, the
molecular weight of PEI should be preferentially smaller than
25 000 g mol1 in order to minimize in advance any adverse
effects of integrated components in the drug delivery system on
biological systems.55,56,58,59 Second, passive targeting of various
polyplexes to tumor tissues is also given triggered by the EPR
effect,4,54,56,58 partly accompanied by higher uptake of poly-
plexes in tumor tissue. Third, some interesting results on
in vitro/in vivo NTSPEI results are provided by the groups of
Appelhans and Aigner:55,56 polyplexes based on NSTPEI and
siRNA are more stable in increasing concentration of extra-
cellular matrix material heparin than polyplexes composed of the
parental PEI. In contrast, other reports stated that the polyplexes
are destabilized significantly when the sugar decoration is slightly
increased on PEI or PAMAM scaffolds. Biodistribution of polyplexes
with siRNA and NTSPEI in nude mice revealed that preferred
uptake of these polyplexes is given in the lung and spleen, but less
in the muscle, kidney and liver.55 This biodistribution is slightly
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unusual when comparing other biodistribution of polyplexes or the
drug delivery system. In addition, tailoring the DNA polyplex admin-
istration56 preferred uptake and molecularly active Luciferase assays
are only observable by intraperitoneal injection and no uptake
was observed at all in the case of intravenous injection. Moreover,
the highest gene transfer activity is recognizable by using the
dense shell architecture of PEI (Fig. 18: structure A = PEI-(2-Mal))
which possesses the lowest cationic charge in this series.56 This is
in contrast to the general opinion that too low cationic charge and
too high sugar decoration in non-viral vectors do not lead to high
transfection efficiency. Finally one has to state that each vector
system based on PEI or PAMAM scaffolds has its specific features
that have to be optimized to be successfully applied in future
gene therapy.
8. Conclusions
In this review, we have outlined the beneficial aspects of
dendritic glycopolymers designed for application in the fields
of drug delivery systems, polymeric therapeutics and diagnostics
in brain diseases. In these specific research fields preferential
dendritic polyamine scaﬀolds have been used and decorated
with diﬀerent mono-, di- and oligosaccharides. To understand
the biological interactions of these dendritic glycopolymers
in vitro and in vivo, examples are given for the interplay of
dendritic glycopolymers with low and high molecular weight
drugs, peptides, proteins and polynucleotides. These complexa-
tion studies reveal the specific characteristics of open and dense
shell dendritic glycopolymers. One large advantage of all these
oligosaccharide-decorated dendritic polyamine scaﬀolds is
their high in vitro and in vivo biocompatibility compared to
the parent dendritic polyamine macromolecules but still paired
with the potential for specific (bio)molecular interactions.
Overall, the interplay of surface composition, charge density,
size of dendritic polyamine scaﬀold, and shell density of dendritic
glycopolymers dictate their final complexation and (biological) inter-
action characteristics against drug and analyte molecules and larger
biological molecules and entities, but also the ability to cross
biological barriers, especially the blood–brain-barrier.
Especially, open shell dendritic glycopolymers, based on
dendritic PPI and PEI cores, are very suited for the delivery of
anionic drugs and poor water-soluble drugs, while open shell
dendritic glycopolymers, based on dendritic PAMAM and PEI
Fig. 18 In vivo eﬃcacy of various (OM-)PEI–DNA complexes as indicated by luciferase transgene expression. Luciferase activity was determined 24 h
(black bars) and 48 h (grey bars) after intravenous (A) or intraperitoneal (B) complex injection. Most efficient dendritic glycopolymer is maltose-modified
PEI with structure A [PEI-(2-Mal)] considered as dense shell in Fig. 8. Reproduced with permission from ‘‘D. Gutsch, D. Appelhans, S. Ho¨bel, B. Voit and A.
Aigner, Mol. Pharmaceutics, 2013, 10, 4666–4675’’. Copyright 2013 American Chemical Society.
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cores, are mainly selected for the transport of RNA and DNA
macromolecules to cells and tissues. In this context targeting
sugar-modified dendritic polyamine scaﬀolds partially facilitate
the cellular uptake of drugs in specific cell lines (e.g. cancer or
dendritic cells) and tissues (e.g. lung or liver). Thus cationic and
H-bonds-active open shell dendritic glycopolymers exhibit a great
potential in the delivery of various drugs as well as biomacro-
molecules and can be designated as promising alternative
delivery systems to (PEGylated) dendritic nanocarrier systems.
The biological use of dense shell glycodendrimers is still
exclusively directed to sugar-decorated dendritic PPI scaﬀolds.
This specific macromolecular architecture is characterized by
a neutral surface charge and an H-bond-active sugar shell.
This kind of ‘‘sugarball’’ can be used as an anti-Alzheimer
and anti-prion agent, but is also applicable as drug to inhibit
prion strain infections of prion protein-containing cells. In a
first in vivo study dense shell glycodendrimers have been proven
to be involved in retaining the memory ability of mice infected
by Alzheimer Ab peptides.
The intensive studies carried out so far demonstrate clearly
that there is a complex interplay between the molecular para-
meters of dendritic glycopolymers and their specific biological
interactions. Therefore, the potential of these specific macro-
molecular architectures in biomedical applications can only be
exploited with a deep understanding of these interactions and,
finally, a careful design of the dendritic, multifunctional structure.
However, the findings so far demonstrate the specific advantages of
dendritic glycopolymers and their general suitability in therapy.
The gained knowledge paves the way for the design and fabrication
of a more sophisticated dendritic glycoarchitecture and to finally
translate them into nanomedicine.
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